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ABSTRACT
This thesis is an exploration of certain aspects of breast-conserving surgery. It 
examines the risk factors as well as implications of local recurrence. All relevant 
published literature has been reviewed. The core of this thesis deals with a 
review of 752 patients who underwent breast-conserving surgery for invasive 
disease. Of these, 543 patients had tumour margin assessment performed by 
histopathological analysis of shavings from the residual cavity following initial 
wide local excision. The incidence of tumour bed positivity was 37%. A 
proportion of these patients underwent further surgery. At a mean follow-up of 
52 months the local recurrence rate was 2%. Tumour bed positivity was found to 
be associated with symptomatic presentation; poorer tumour grade; 
lymphovascular invasion; extensive in-situ disease within the tumour and 
mammographically-detected casting calcification as well as absence of a nidus. 
Tumour bed positivity was found to predict for both poorer disease-free and 
distant disease-free survival. Furthermore, following introduction of tumour bed 
assessment the local recurrence rate fell from 16 to 2.5%. The implications of 
these findings are expanded upon in the following work.
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INTRODUCTION
EPIDEMIOLOGY OF BREAST CANCER
The incidence of breast cancer is higher in western countries than in the third 
world. When immigration occurs from a low to a high-risk country an increase 
in the incidence of breast cancer is observed (1). This risk is present within 
subsequent generations of the migrant population and reflects the incidence of 
the disease within the high-risk country (1). This suggests that there are social 
and environmental factors within a community, which may contribute to the 
incidence of breast cancer (1). Between 1983 and 1987 the world 
standardised incidence of breast cancer in Scotland was 62.60 per 100,000 of 
the population, compared to the incidence in England and Wales of 56.10 per
100.000 of the population (1). The incidence of disease in England and Wales 
is lower than most other developed countries, where the incidence of breast 
cancer ranges from 66.20 per 100,000 of the population in France to 89.20 per
100.000 in the U.S. A (1). However, the incidence of breast cancer is rising 
throughout the western world with 30,056 new cases being diagnosed in 
England and Wales in 1992 alone (1).
In 1992 breast cancer caused 13,663 deaths in England and Wales accounting 
for 4.8% of all female deaths (1). Apart from ischaemic heart disease breast
17
cancer was the largest single contributor to female mortality (1). These figures 
for breast cancer-related mortality translate to 39.47 deaths per 100,000 of the 
population within England and Wales alone (1). Deaths fi'om breast cancer are 
higher within the U.K than most other western nations, with the exception of 
Denmark (1).
In 1991 the government published a white paper entitled The Health o f the 
Nation in which strict targets and objectives were laid out in order to improve 
the nation’s health care by the year 2000. One target set, was a 25% reduction 
in breast cancer-related mortality, especially within the screen-detected 
population. This would mean an U.K-wide reduction in breast cancer-related 
deaths from 93.6 per 100,000 in 1990 to 72.7 per 100,000 by the year 
2000 (1).
In Scotland since 1959 there has existed through the Scottish National Cancer 
Registry a means whereby epidemiological data could be collected and 
analysed. The Scottish Cancer Trials Group has used such data to assess 
changes in the trends of breast cancer presentation and management over the 
past decade. From 1987 to 1993 there was an increase in the number of 
patients with breast cancer referred by General Practitioners to units 
specialising in the treatment of this disease (2). In 1987, specialist surgeons
18
saw 35% of new breast cancer cases compared with 57% in 1993 (2). A 
response by the government to reduce the mortality rate from breast cancer 
led to mass population screening being introduced for all women within the 
50-64 year age group. Mass screening was initially introduced into Scotland in 
1987 and to the rest of the U.K from 1991 onwards. In 1987 only 4% of 
breast cancers treated within the screening age range were screen-detected 
(2). However, in 1993 this figure had risen to 49% (2). Similarly in other 
European countries mass screening for breast cancer was introduced at the 
same period of time. In the Netherlands for example, in 1990 when screening 
started, 355 new cases of breast cancer were detected by this method (3). In 
1993 however, this rose to 1450 new cases, a 17% increase on the non­
screened figures (3). From 1997 onwards there is expected to be a steady 
3.5% increase in tumour detection as a result of screening (3). Due to the 
increased detection of smaller operable tumours as a result of mass screening, 
there is expected to be a rise in the number of tumours treated by breast- 
conserving surgery. In the Netherlands between 1983-84, 33% of tumours 
were treated by breast-conserving surgery (3). This figure is expected to rise 
to 55% of all newly diagnosed breast tumours by the year 2000 (3). Despite 
these results screening has some limitations. Mushlin et al performed a meta­
analysis of the results from several screening trials (4). This team found that 
the true-positive rate varied from only 83% to 95% (4). There was also a
19
significant false-positive rate of up to 6.5% that invariably would lead to 
unnecessary morbidity (4). Furthermore, screening is associated with 
significant radiation exposure (5). This has resulted in certain quarters 
questioning the validity of screening (6).
Within the Greater Glasgow Health Board district among the 35% of women 
within the screening age range, compliance of screening was 66% (2). 
Furthermore, compliance was not found to be affected by socio-economic 
status (2). As a direct impact of screening, there was an increased incidence of 
clinically stage I and axillary node negative tumours being detected (2). Due 
to a combination of screening and increased patient awareness of breast 
cancer, more patients were presenting earlier with smaller tumours, which 
were amenable to breast-conserving surgery (2). This factor along with an 
increased acceptance of breast-conserving surgery as an alternative to 
mastectomy by the surgical community, led to an increase in the use of breast- 
conserving surgery (2). In 1987, 40% of breast cancer cases were treated by 
breast-conserving surgery and this figure rose to 52% in 1993 (2). Along with 
the increased use of this surgical technique, there also occurred an increase in 
the number of patients being offered adjuvant therapy (2). In 1987, 70% of 
breast cancer patients were offered adjuvant therapy compared to 96% in
20
1993 (2). This rise was as a result of both an increased use of hormonal as 
well as cytotoxic chemotheraputic agents (2).
In summary breast cancer is a common form of cancer that forms a 
challenging clinical problem. Its incidence appears to be increasing.
However, with the advent of screening resulting in earlier detection as well as 
an improvement in adjuvant therapeutic measures it is hoped that the mortality 
from this disease could be reduced. There has been data published that has 
shown a fall in the mortality from breast cancer (7). These results are most 
marked in the United States however (7). Furthermore, results from the 
Gothenburg screening trial have shown an improvement in the mortality rates 
of women as a result of screening thus validating the immense expense 
involved in undertaking such a mass screening programme (8).
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HISTORY OF BREAST CANCER SURGERY
Although cases of breast cancer being treated surgically date back to Egyptian 
physicians in 3000 B.C, it was not until the mid-nineteenth century that with 
the discovery of antiseptics and anaesthesia, surgical management of breast 
cancer became a viable option. The discovery of the microscope, which led to 
the expanding science of cell biology, for the first time led pathologists to 
make a histological diagnosis of breast cancer.
In 1867, Charles Moore a surgeon in the Middlesex and St. Lukes hospital in 
London, published a paper in which he detailed what he believed were general 
principles on which breast cancer surgery should be based. In a study of 14 
patients he noted that all local recurrences occurred at the site of the previous 
surgery (9). This led him to suggest that local recurrence was due to 
inadequate tumour excision (9). He concluded that the minimal amount of 
surgery that should be performed for cases of breast cancer should be a 
mastectomy. Charles Moore also advised an en-bloc dissection of the axilla in 
cases where nodal involvement was clinically suspected (9).
In the late nineteenth century, pathologists discovered the presence of tumour 
deposits within the pectorialis major muscle and fascia. This contributed
22
towards a call for more radical surgery in the management of breast cancer. In 
1907 William Halsted published the results from 232 operations for breast 
cancer (10). Halsted routinely performed resection of the breast tissue along 
with a wide resection of the overlying skin and excision of the pectorialis 
major muscle. Following mastectomy the wound would be closed by skin 
grafting. He also performed resection of the axillary nodes in all patients. 
Halsted achieved a 3-year survival of 38.3% following his radical mastectomy 
procedure (10). This survival figure showed a halving of the mortality rates 
when compared with the results obtained by his contemporaries (10).
Towards the beginning of the twentieth century however, the efficacy of 
radical surgical procedures for the treatment of breast cancer were being 
questioned. In an overview of the previously published literature by Lane- 
Claypon in 1924, the results of 20,000 operations were analysed 
retrospectively (11). All patients who were lost to follow-up and those without 
a pathological diagnosis of breast cancer were excluded from this study. 
Although this study suffered from the hazards of a retrospective, non­
randomised clinical trial, it did however show that the traditional Halsted 
mastectomy procedure was associated with a 29.2% three-year survival 
compared to a 43.2% survival for less radical forms of surgery (11).
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The accepted theory about the spread of breast cancer in the late nineteenth 
century as proposed by Halsted, was that secondary tumour deposits occurred 
as a result of a non-breaking chain of tumour cells arising from the primary 
site and travelling along lymphatic channels to the site of distant disease (10).
It was not until 1936 that this theory was questioned when pathologists 
showed the presence of anatomically normal lymphatic channels between the 
primary tumour and axillary nodal disease (12). In 1938 a modification of the 
traditional mastectomy procedure was proposed by Patey and Duson (13).
They raised skin flaps in order to allow excision of the breast tissue followed 
by primary closure of the wound thus negating the need for skin graftmg. This 
team also left the pectorialis major muscle intact. This operation was the 
forerunner of the simple mastectomy procedure commonly used to date.
With the advent of radiotherapy interest grew in less radical forms of surgery 
in order to reduce the extremely high rates of patient morbidity and mortality. 
An important breakthrough in the usage of radiotherapy came with the 
introduction of supravoltage radiation therapy equipment in the late 1950’s. 
This equipment allowed for the first time a homogenous dosage of radiation to 
the breast with minimal radiation scatter to the surrounding organs. With the 
availability of radioisotopes, such as lrridium-192 the use of a boost dose to a 
selected part of the breast became possible. More recently with electron beam
24
irradiation it has become possible to perform a boost dosage on a more 
convenient outpatient basis.
The first clinical trial conducted showing comparable rates of survival 
between the traditional radical mastectomy and simple mastectomy (combined 
with post-operative radiotherapy) was started in Copenhagen in 1951 (14).
This trial consisted of 666 patients prospectively randomised to either radical 
mastectomy or simple mastectomy followed by post-operative radiotherapy.
In both cohorts only 76% of patients were treated according to the trial 
protocol due to either tumour in-operability or patient refusal of surgery. 
Despite this limitation however, no difference in patient survival was observed 
between these two cohorts (14).
Since the 1970’s there have been five prospective randomised trials that have 
compared breast-conserving surgery to mastectomy (Table 1). One of the 
largest European trials was fi*om the National Cancer Institute of Italy in 
Milan, this trial evaluated results on 701 women between 1971 and 1980 with 
primary tumours of 2cm or less (15). In this trial conservation surgery 
consisted of a quadrantectomy and a level 3 axillary dissection. Post-operative 
radiotherapy consisted of a 50Gy dose to the breast over 5 weeks followed by 
a lOGy boost to the tumour bed. During the course of this trial a change to the
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treatment protocol was introduced in 1975 when all patients with involved 
nodes were treated with adjuvant chemotherapy consisting of 12 cycles of 
CMF. Despite the potential inaccuracy introduced by this change in treatment 
protocol during the course of an on-going trial, the Milan trial found no 
survival advantage of mastectomy over breast-conserving surgery. 
Furthermore the breast-conserved cohort had a low local recurrence rate of 
only 0.3% (15).
The National Surgical Adjuvant Breast and Bowl Cancer Project (NSABP) 
began a three-armed trial (protocol B-06) in 1976 comparing mastectomy with 
segmental resection with or without radiotherapy (16). A total of 1843 
patients with tumours up to 4cm in diameter were included in the study by its 
closure in 1984. All patients underwent axillary dissection. Those with 
positive nodes received adjuvant chemotherapy with Melphalan and 5- 
Flurouracil. Conservation surgery consisted of excision of the primary with 
enough surrounding tissue to ensure a tumour free inked margin. In 10% of 
patients however a positive margin was present and these patients went onto a 
completion mastectomy. Radiotherapy was delivered to the breast at a dose of 
50Gy but without an additional boost to the tumour bed. The 8-year results 
from the NSABP trial showed that 39% of patients not receiving radiotherapy 
developed local recurrence compared to 10% in those who received post­
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operative radiotherapy (16). However despite this difference in local 
recurrence rates no significant survival advantage of mastectomy over breast- 
conserving surgery was found (16).
The results fi'om these trials lead to a change in surgical opinion favouring 
breast-conserving as a viable alternative to mastectomy. The implementation 
of mass screening as well as increased patient awareness of breast cancer has 
led to an increasing number of patients presenting with smaller tumours that 
are suitable for breast-conserving surgery (2). This, along with patients 
demanding a better cosmetic result following surgery has further increased the 
use of breast-conserving surgery as an alternative to mastectomy in the 
management of breast cancer. The increasing preference for breast-conserving 
surgery has been reflected in epidemiological data (2).
Breast-conserving surgery offers a better cosmetic result, reduced patient 
morbidity and a shorter in-patient stay. However, this type of surgery is 
dogged by one significant complication - that of recurrence within the 
ipsilateral breast. From Table 1 it can be seen that local recurrence rates 
following breast-conserving surgery vary fi'om 0.3 to 15%. These diverse 
figures represent differences in both patient selection; the aggressiveness of
27
surgical excision for example quadrantectomy versus lumpectomy; as well as 
post-operative radiotherapy regimens within these varying trials.
Local recurrence not only undermines patient morale but may lead to 
mastectomy, thus defeating the initial purpose of breast-conserving surgery. 
More recently however, local recurrence is being seen by clinicians in a more 
sinister light as the harbinger of systemic recurrence. There are several 
recognised risk factors for the development of local recurrence that will now 
be explored in greater detail.
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Table 1: Prospective randomised clinical trials comparing 
breast-conserving surgery and mastectomy
Trial N um ber
o f
patients
T um our
diam eter
(cm )
R adiotherapy
regim en
Follow -
up
(years)
O verall
survival
Local
recurrence
M IL A N  I 701 <2 50 Gy
10 Gy boost to 
tumour bed
13 71% for 
Quadrantectomy
69% for 
Mastectomy
0.3% for 
Quadrantectomy
N SA B P -
B06*
1843 <4 50 Gy
No boost to 
tumour bed
9 69% for
Lumpectomy
68% for 
Mastectomy
12% for 
Lumpectomy
W H O 179 <2 45 Gy
15 Gy boost to 
tumour bed
10 77% for 
Lumpectomy
75% for 
Mastectomy
NCI 247 <5 48 Gy
15-20 Gy 
boost to 
tumour bed
10 77% for
Lumpectomy
75% for 
Mastectomy
5 % for 
Lumpectomy
10% for 
Mastectomy**
EO R TC 878 <5 50 Gy
25 Gy boost to 
tumour bed
8 73% for 
Lumpectomy
71% for 
Mastectomy
15% for 
Lumpectomy
10% for 
Mastectomy**
•  In all above trials there w^ as no statistically significant difference in overall survival 
between the mastectomy and breast-conserving surgery cohorts
* Result at 10-year follow-up
** Loco-regional recurrence rates for patients undergoing a mastectomy
29
RISK FACTORS FOR LOCAL RECURRENCE
The identification of risk factors associated with the development of local 
recurrence following breast-conserving surgery is of potential use in refining 
patient selection criteria and treatment modalities. There are however 
significant methodological problems involved in assessing the risk factors 
associated with local recurrence in the breast.
There are a multitude of publications looking specifically at this issue. These 
vary from small retrospective studies to prospective trials of varying size.
Most of these studies use differing statistical methods to analyse the data. 
Furthermore, the results obtained often vary in respect to the specifics of the 
type of breast-conserving procedure or adjuvant therapy used. For example, 
factors associated with local recurrence following quadrantectomy may well 
be different from those following a lumpectomy. Thus differences in patient 
selection, radiation dose, boost volume and the use of adjuvant systemic 
therapy will all have an influence on the factors found to be predictive of local 
recurrence within the breast.
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CLINICAL FACTORS
Patient age and hormone replacement therapy
Young age has been found to correlate with increased risk of local recurrence 
in several studies (17-23). Of these however, only the study by Veronesi was 
a prospective randomised trial (17). In this study 579 women with 
pathological tumour diameters of less than 2.5cm were randomised to 
quadrantectomy with or without post-operative radiotherapy. Veronesi found 
that there was a significant fall in the local recurrence rate associated with 
older age (17). Women younger than 55 years had a local recurrence rate of 
17.5% compared to only 3.8% in those aged over 55 (17). This study has 
however several limitations. Firstly, although Veronesi found that an extensive 
in-situ component within the tumour also predicted for local recurrence a 
multivariate analysis was not performed in order to identify whether age was 
an independent predictor of local recurrence. Furthermore, when assessing the 
impact of clinico-pathological factors on local recurrence Veronesi’s team 
only assessed those 273 patients that underwent quadrantectomy alone rather 
than the total cohort of 579 patients. These factors further undermine the 
validity of the above results.
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Kurtz performed a retrospective analysis of 586 patients treated by breast 
conserving surgery and found that on univariate analysis younger age 
predicted for local recurrence (19). However, this relationship was lost on 
performing a multivariate analysis (19). These results may well be biased by 
the fact that even when a positive margin was present no attempt at re­
excision was performed. Furthermore, there is no formal mention of the 
numbers of patients with a positive margin and margin involvement was not 
included within the final multivariate analysis. Similarly Fourquet performed a 
retrospective analysis on 563 patients with “early” breast cancer and found 
that in both a univariate as well as a multivariate analysis younger age was a 
predictor of local recurrence, relative risk o f2.44 (20). Although this study 
provides the strongest evidence that younger age is a predictor of local 
recurrence, Fourquet’s work is limited by the fact that it is retrospective in 
nature with no form of randomisation. Furthermore, the patients had been 
collected fi'om 1960 to 1980, a time fi-ame over which there would inevitably 
have been changes in the adjuvant therapy used. This is highlighted by the fact 
that only 53% of the patients received a radiation boost to the tumour 
bed (20).
The shortcomings of the above studies do suggest that the relationship 
between patient age and its risk for the development of local recurrence is
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difficult to quantify. This is partly due to the fact that there are often only 
small numbers of patients who fall within the young age category, for example 
in the study by Sismondi only 35 patients were aged less that 35 thus making 
any subsequent statistical analysis subject to question (23). Also, most studies 
dealing with this issue have tended to use random and differing cut off 
between the “younger” and “older” patients further confusing subsequent 
analysis. Furthermore, younger age has been associated with the presence of 
poorer tumour grade; extensive intra-duct component within the tumour as 
well as the presence of lymphovascular invasion and inadequate tumour 
excision - all of which have been recognised as independent risk factors for 
the development of local recurrence (19-23).
For several decades oestrogens and progestagens have been prescribed to 
replace the cyclical production of ovarian hormones that normally ceases after 
the menopause. Several studies have shown that long-term use of hormone 
replacement therapy is associated with an increased risk for the development 
of breast cancer (24-25). The “collaborative group on hormonal factors in 
breast cancer” published a major work analysing the relationship between 
hormone replacement therapy and breast cancer (24). A meta-analysis was 
performed of 51 epidemiological studies and a total of 161,106 patients. This 
study found that the risk of developing breast cancer in women who were
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greater than 5-years post-menopausal fell by 2.7% every year (24). 
Furthermore, those women on hormone replacement therapy, who had been 
on this medication for less than five years, the relative risk of developing 
breast cancer was 1.023 (24). In women taking hormone replacement therapy 
for greater than 5-years this relative risk rose to 1.35 (24). Although meta­
analysis is a strong statistical tool and provides some useful information there 
are however some drawbacks to this type of study. Firstly, although a total of 
21 countries were represented within this study the majority of the 51 papers 
examined were fi'om the United States and Northern Europe. This inevitably 
leads to a bias. Also, the majority of women with breast cancer included 
within this analysis were diagnosed in the early 1980’s. At that time the type 
of hormone replacement therapy used was predominantly oestrogen based 
with only 12% of women within this trial being on a combined oestrogen and 
progestrone prescription (24). Modem hormone replacement therapy 
prescriptions consist of combined preparations and thus their impact on the 
risk of developing breast cancer may well be totally different. Furthermore, 
there is little data available on the impact of long-term hormone replacement 
therapy on the risk of developing breast cancer.
Although there appears to be a relationship between hormone replacement 
therapy and breast cancer. Bonnier found that in those patients developing
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breast cancer following hormone replacement therapy use, the tumours were 
usually smaller, less pleomorphic and tended to be node negative (26). Also, 
in this study no increased risk of either local or systemic recurrence among 
those tumours associated with hormone replacement therapy use was found 
(26). There is however one major weakness of this trial. The data presented 
was collected retrospectively and in a non-randomised manner between 1985 
and 1995. Thus the differences in patient outcome seen between the hormone 
replacement therapy users and non-users may be down to chance.
Although the data published to date suggest that long term use of hormone 
replacement therapy is associated increased risk of developing breast cancer, 
it appears that these cancers are usually less aggressive. However, despite 
these findings there remains the need for further investigation into this subject.
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Family history
Although between 5-10% of breast cancers are familial due to the relatively 
small numbers of such patients, there have been few studies dealing with 
familial breast cancer and its association with poorer outcome. Furthermore, 
most of these studies grade patient as having familial breast cancer based on 
hospital records and these may have an inherent inaccuracy.
Harrold et al published data suggesting that there was no relationship between 
familial breast cancer and an increased risk of local recurrence (27). In this 
study a retrospective analysis of 984 patients was performed. Of these 
patients 15% went onto develop local recurrence (27). However, of the total 
of 112 patents developing local recurrence, only 52 of these patients were 
chosen at random and included in the analysis of the risk of local recurrence. 
Furthermore, both the control and study group had significant variations in 
both tumour margin positivity as well as nodal status. This combined with the 
fact that any analysis of such small numbers has limited power makes this 
study inherently flawed.
In a study by Chabner et al a total of 201 patients younger than 36 years of 
age were analysed and those patients with and without familial breast cancer
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were compared with each other (28). Chabner found that those patients with 
familial breast cancer had an increased of developing cancer in the opposite 
breast, relative risk of 5.7 (28). However, there was no association between 
familial cases and poorer local control or overall survival (28). Although these 
results are interesting, they are limited by the fact that of the 201 patients 
within the study only 29 had familial breast cancer. Furthermore, the criteria 
that were used to diagnose a patient with familial breast cancer within this 
study were the presence of a sister or mother with breast diagnosed before the 
age of 50 years. Thus this study underestimates the true incidence of familial 
breast cancer, as patients with more distant relatives as well as paternal 
relatives are not included within the analysis. Also, this study deals with only 
young patients with breast cancer and thus is unrepresentative of a vast 
majority of patients with breast cancer.
In summary there has been no good evidence that familial breast cancer is 
associated with increased risk of local recurrence. This may be explained by 
however by the small numbers of patients with familial breast cancer.
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Mammographie features
In order to reduce the morbidity associated with a positive tumour margin 
necessitating re-excision, pre-operative identification of the risk factors for the 
development of local recurrence can be extremely useful in influencing the 
extent of primary surgery. The vast majority of patients with breast cancer 
undergo pre-operative mammograms. Macmillan et al performed a study in 
which pre-operative mammographie features were correlated with recognised 
clinico-pathological risk factors for the development of local recurrence (29). 
A total of 231 patients undergoing breast-conserving surgery had their pre­
operative mammographie features assessed by a single radiologist blinded to 
the pathological data (29). In this study, an extensive intra-duct component 
within the tumour was significantly associated with the absence of 
mammographie nidus, presence of stellate nidus and casting micro­
calcification (29). Furthermore, a dense mammographie pattern, casting 
calcification and absence of mammographie nidus all predicted for tumour bed 
positivity (29). All these features are recognised risk factors for the 
development of local recurrence (14,29-30). The limitation of the above study 
however is that the group of patients with each of the fore mentioned 
mammographie features is relatively small thus any statistical analysis of such 
data is weak. Also, the primary statistical tool used in this study was a
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univariate analysis. This test is inherently weaker than a multivariate analysis, 
which if performed would identify those mammographie features that are 
independent predictors of local recurrence.
Liljegren et al performed a prospective randomised trial on 381 patients 
treated by breast-conserving surgery (30). In this study pre-operative 
mammographie features were recorded and were analysed separately as risk 
factors for the development of local recurrence. Liljegren found that on 
univariate analysis the presence of a stellate lesion with calcification was 
associated with an increased risk of developing local recurrence, relative risk 
of 3.8 (30). This factor correlates well with Macmillan’s data. However, 
Liljegren also found that a non-stellate lesion and the absence of calcification 
was also associated with an increased risk of local recurrence, relative risk of 
2.3 (30). This result appears to contradict Macmillan’s data. However, when a 
multivariate analysis was performed the only mammographie feature that 
independently predicts for local recurrence was a stellate lesion associated 
with microcalcification, relative risk of 4.5 (30). Although the adequacy of 
tumour excision is important in local control, these pre-operative 
mammographie features may assist the surgeon in planning the extent of 
primary surgery.
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TUMOUR FACTORS
Tumour diameter
Many studies have analysed the relationship between tumour diameter and the 
risk of local recurrence. In the EROTC trial when tumours greater or less than 
2 cm in diameter were compared, increasing tumour diameter was not found 
to be a predictor of local recurrence (31). This trial consisted of 902 patients 
with stage I and II cancers randomised to either breast-conserving surgery or 
mastectomy. This study has several disadvantages however. Firstly any 
patients with a positive tumour margin were excluded from the trial and this 
will inevitably bias the subsequent results. Furthermore, analysis of tumour 
diameter as a predictor of local recurrence was based on a clinical 
measurement, which is inherently inaccurate. Similarly, in the Marseilles study 
no association was found between tumour size and local recurrence (19). This 
study was performed in a retrospective manner analysing the outcome of 496 
patients treated by breast-conserving surgery (19). Although a positive margin 
was found in 10% of cases and in a further 37% of cases a confident 
assessment of the margin status could not be performed, no attempt at re­
excision was made (19). This finding suggests that in a vast proportion of the 
patients within this trial the primary surgery was inadequate and this fact may 
well have biased the subsequent results.
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There have been several studies that have found a positive correlation 
between increasing tumour size and local recurrence (Table 2). One major 
study published from the United States was the NSABP-B06 trial (16). A total 
of 1843 patients with tumours up to 4cm in diameter were included in the 
study. Conservation surgery consisted of excision of the primary with enough 
surrounding tissue to ensure a tumour free inked margin. In 10% of patients a 
positive margin was present and these patients went onto a completion 
mastectomy. On performing a univariate analysis pathological tumour size 
was found to predict for local recurrence (16). This relationship remained 
significant on a subsequent multivariate analysis, relative risk of 1.57 (16). 
There is however one flaw within the trial design that may have biased these 
results however. Namely the 10% of patients who underwent a completion 
mastectomy for a positive margin were included in the breast-conserved 
cohort for the final analysis. This fact makes interpretation of the results from 
this trial fraught with difficulty.
Veronesi et al performed a retrospective study between 1970 and 1987 on 
2233 patients undergoing quadrantectomy and axillary clearance followed by 
radiotherapy to the breast (32). Pathological tumour size was subsequently 
stratified into four groups. This study showed that on a multivariate analysis 
the largest tumours (>2cm) predicted for local recurrence when compared to
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tumours less than 0.5cm, relative risk being 3.159 (32). It should be noted 
however that the breast-conserving procedure adopted by Veronesi consists of 
a quadrantectomy and is more extensive a resection than used by most teams. 
Thus the results from this trial cannot be easily extrapolated to patients who 
have been treated by more limited primary surgery.
Holland et al looked at the issue of tumour multifocality by serially sectioning 
282 mastectomy specimens of patients suitable for breast-conserving surgery 
(33). This group found that at a 2cm margin from the primary tumour 43% of 
cases had residual disease (33). This figure correlates well with the local 
recurrence rates of the “lumpectomy alone” arm of the NSABP-B06 trial (16). 
Furthermore, there was no association between tumours less than or greater 
than 2cm and an increased incidence of residual microscopic disease around 
the tumour (33). This suggests that the association between tumour diameter 
and local recurrence may simply reflect the fact that larger tumours make a 
complete surgical excision more difficult. Thus any correlation between 
tumour diameter and local recurrence may merely be due to the adequacy of 
local excision protocols practised within each of the above studies.
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Table 2: Tumour size versus local recurrence
Study P-value Relative Risk
NSABP-B06 0.001 1.57
Veronesi et al 0.0183 3.159
Deore et al <0.05 Not available
OCOG 0.01 1.64
Bonnier et al 0.005 1.75
p-values represent results of analyses comparing increasing tumour size and risk of 
local recurrence
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Extensive intra-duct component within tumour (EIC)
Several clinical trials have shown that an extensive intra-duct component 
within the tumour (EIC) to be an independent risk factor for the development 
of local recurrence (17,32, 34-37) (Table 3). However, one factor that makes 
a comparison of these various studies difficult is the fact that often different 
researchers used differing definitions for EIC. One widely accepted definition 
of EIC is greater than 25% of the primary tumour containing in-situ disease 
(37). In the Milan III trial following quadrantectomy, the local recurrence rate 
fell fi'om 16.7% for patients with EIC to 7.4% in those without EIC (17). This 
trial however has two serious design flaws. Firstly, all patients with a positive 
margin were excluded from the study. Secondly, the analysis of the risk 
factors for the development of local recurrence was performed in only the 
273/567 patients within the trial who did not receive adjuvant post-operative 
radiotherapy. Similarly, Veronesi’s review of 2233 women treated by 
quadrantectomy between 1970 and 1987 showed that the presence of EIC 
predicted for local recurrence (32). Interestingly, although a total of 119 
patients developed local recurrence, the final analysis was only performed on 
115 patients, as 4 patients who developed local and systemic recurrence 
spontaneously were re-grouped within the systemic recurrence cohort (32). 
Also of note is the fact that of the 119 patients with a local recurrence
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histological information was present on only 100 patients and thus only a 
proportion of patients with local recurrence could be assessed for the presence 
of EIC (32). Furthermore, this team did not provide a definition of EIC and 
the pathology was not reviewed by a single pathologist thus the criteria that 
this team used to define patients as having EIC are open to question. It should 
also be noted that in both the above trials patients underwent a 
quadrantectomy, which involves a more extensive resection than commonly 
used. Thus it is may not be possible to extrapolate this data to patients 
undergoing more limited resections.
Sinn et al reviewed a total of 957 patients treated by breast-conserving 
surgery between 1985 and 1992 (34). All the histological slides were 
reviewed and re-graded. Interestingly Sinn’s definition of EIC was related to 
the ratio of the in-situ component to the invasive component. Tumours were 
graded as having either EIC if the in-situ component was two times the size of 
the invasive component or as having a predominant intra-duct component 
(PIC) if the in-situ disease was four times the size of the invasive disease (34). 
In this study the local recurrence rate was 6% (34). On a univariate analysis, 
the presence of EIC/PIC was associated with local recurrence (34). This 
relationship remained significant when a multivariate analysis was performed, 
relative risk of 1.90 (34). A similar study by Borger et al, where the pathology
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of 969 patients who underwent breast-conserving surgery was reviewed and 
outcome analysed, revealed that EIC was a predictor of local recurrence (36). 
This relationship did not however remain significant on a subsequent 
multivariate analysis. Similar results were found in the Marseilles trial where 
EIC was found to predict for local recurrence (37). Interestingly the presence 
of in-situ disease at the edge of the tumour was also associated with local 
recurrence (37). However, this relationship may well be biased by the fact that 
in the vast majority of cases in-situ disease within the periphery of the tumour, 
EIC is also present.
The only major trial where no association between EIC and local recurrence 
was found was in the NSABP-B06 trial (38). One possible explanation for this 
may be that patients who had a mastectomy performed for positive resection 
margins were included in the analysis as part of the cohort treated by breast- 
conserving surgery. Thus the data firom this trial may well be skewed.
In summary there have been a number of studies that have shown EIC to be a 
risk factor for local recurrence. Furthermore Sinn et al showed that the 
relationship between EIC and local recurrence is also determined by the 
relative proportional size of the in-situ to the invasive component. This 
relationship may be due to the fact that a large intra-duct component
46
surrounding the tumour may make an adequate tumour excision more difficult, 
thus increasing the risk of local recurrence. There is also data becoming 
available that shows a relationship between the grade of EIC and the risk of 
local recurrence. In a major study by Voogd et al, a total of 7000 breast- 
conserved patients from 11 centres throughout the Netherlands were analysed 
(39). A local recurrence rate of 5% was found (39). All patients had the 
pathology independently reviewed. EIC was defined as being present when 10 
or more ducts within the primary tumour were involved with in-situ disease 
(39). Patients with EIC were subsequently subdivided into those with “high 
grade” comedo or “low grade” cribriform in-situ disease. The presence of 
“low grade” EIC was associated with local recurrence, relative risk of 1.9 
(39). However, an even stronger association was found between “high grade” 
EIC and local recurrence, relative risk of 3 (39).
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Table 3: Presence of EIC versus local recurrence
Study P-value Relative Risk
Milan III 0.04 Not available
Veronesi et al 0.0246 1.877
Sinn et al <0.001 1.9
Leborgne et al 0.0016 Not available
Burger et al 0.025 Not available
Marseille trial <0.001 Not available
BORST <0.01 3
Lindey et al 0.003 Not available
/i-values represent results of analyses comparing EIC and risk of local recurrence
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Tumour grade and type
The presence of poorer tumour grade has been shown in several studies to be 
an independent risk factor for the development of local recurrence (19,21,30- 
31,34,38-40)(Table 4). Sinn et al reviewed the pathological data of 957 
patients treated by breast-conserving surgery and found that on performing a 
multivariate analysis, poorer tumour grade predicted for local recurrence, 
relative risk being 1.76 (34). The important feature of this study is that in all 
patients, the pathology was reviewed by a single independent pathologist. 
This avoids the risk of inter-observer variation. In the NSABP-B06 trial, on 
univariate analysis poorer tumour grade was found to predict for local 
recurrence, relative risk being 1.5 (38). This relationship did not remain 
significant on multivariate analysis however (38).
In Kurtz et aTs review of 586 breast-conserved patients the presence of 
poorer tumour grade was found on multivariate analysis to be a risk factor for 
the development of local recurrence (19). Interestingly, this relationship was 
only significant among patients aged 50 years or older (19). Similarly in the 
review by Bonnier et al of 1266 patients treated by breast-conserving surgery 
between 1976 and 1992, the presence of poorer tumour grade was a predictor 
of local recurrence, relative risk of 2.53 (21). Again, this relationship was only
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significant in-patients older than 35 years of age (21). This age related 
distribution may be explained by the fact that there are relatively few young 
patients with these studies, for example in Bonnier’s cohort of 1266 patients 
only 93 were younger than 35 years of age (21). Thus any underlying 
statistical relationship may not become apparent unless larger numbers of 
patients are recruited within the younger age ranges. In the analysis by Voogd 
et al on 7000 patients, there was a total of 360 local recurrences (39). When 
the risk factors for the development of local recurrence were analysed 
comparing younger pre-menopausal to older patients, the presence of a poorer 
tumour grade was a significant risk factor in both cohorts (relative risk of 1.5 
for the pre-menopausal compared to 1.7 for the post-menopausal patients)
(39). The overall relative risk for the development of local recurrence for 
higher-grade tumours was 2 (39). One limitation of this study however, is the 
fact that tumours were graded according to the mitotic index rather than the 
Bloom and Richardson system that is common place today (39).
Approximately 80-90% of all breast cancers are ductal in nature. There have 
been several publications to date that have analysed the relationship between 
tumours of special type and the risk of local recurrence following breast- 
conserving surgery (34,38,40-41), In a pathological review performed by 
Kurtz et-al on 861 stage I and II tumours treated by breast-conserving surgery,
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the local recurrence rate was 13.5% at 5 years for lobular carcinoma 
compared with 8.8% for ductal carcinomas (41). However, this difference was 
not shown to be statistically significant (41). This may however be explained 
by the fact that within this study there were only 67 patients with lobular 
carcinoma (41). Similarly in the study by Lindey et al there was no association 
between tumours of special histological type and local recurrence (40). Again 
the limiting factor in this study is the fact that the numbers of such tumours are 
limited (40). In Sinn’s review however, there was a relatively large series of 
lobular carcinomas amounting to 14.2% of the total number of patients 
included within the study (34). Sinn et al found that the 5-year local control in 
invasive ductal carcinomas was 94.8% compared to 88.2% in the patients with 
lobular carcinoma (34). It was noted however that this difference in outcome 
took 3 years of follow-up to become apparent (34). This may be explained by 
the fact that the early local recurrences, within the first 3 years, are as a result 
of inadequate tumour excision, which can occur in both these cohorts. 
However, after 3 years the poorer local control within the patients with lobular 
carcinoma may reflect the multicentric nature of this tumour. Similar results 
were found in the NSABP-B06 trial where lobular carcinomas were found to 
be a significant risk factor for the development of local recurrence, relative 
risk of 2.13 (38).
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In summary poorer tumour grade has been found to be a risk factor for the 
development of local recurrence. This relationship appears to be most marked 
in older patients. However, this may merely representative of the difficulty of 
obtaining sufficient numbers of young patients with breast cancer in-order to 
perform a meaningfiil analysis.
When the 10-15% of patients with breast tumours of special type are analysed 
separately, it appears from the studies published to date that breast-conserving 
surgery is inappropriate for lobular carcinomas. This may be due to the 
multifocal nature of lobular carcinomas that mitigates against a breast- 
conserving procedure providing adequate tumour excision.
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Table 4: Poorer tumour grade versus local recurrence
Study P-value Relative Risk
Kurtz et al 0.001 Not available
Bonnier et al 0.01 2.53
EORTC <0.001 2.28
Sinn et al <0.0001 1.76
NSABP-B06 0.0005 1.5
Voogd et al <0.05 2
Lindey et al 0.0003 3.61
Liljegren et al <0.05 2
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Lymphovascular invasion
The presence of invasion by breast cancer cells of the vascular bundle can be 
a method of tumour dissemination independent of the usual method of spread 
through the lymphatic channels and eventually to the axillary/intemal 
mammary nodes. Lymphovascular invasion is commonly present in 
approximately 22% of breast cancers (34,43). Several studies have however 
shown that the presence of lymphovascular invasion is also a predictor of 
local recurrence (28,30,32,34,36,38,42-43).
Chabner et al reviewed the data on 201 patients treated by breast-conserving 
surgery (28). All the histological slides were reviewed by two independent 
pathologists. Chabner found that lymphovascular invasion was a predictor of 
local recurrence, relative risk being 2.5 (28). This study has two main 
limitations however, firstly the numbers of patients included are relatively 
small with only 70 patients having lymphovascular invasion. Secondly, the 
patients included within this study were all aged 36 years or younger, thus it 
may not be possible to extrapolate these results to the vast majority of patients 
with breast cancer. Similarly Liljegren et al found that lympholvascular 
invasion predicted for local recurrence, relative risk 1,7 (30). Again, this study 
is hampered by the relatively small numbers of patients that were recruited
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into this trial. Furthermore, the post-operative radiotherapy regime did not 
include a boost to the tumour bed and this fact may also have biased the above 
results.
Veronesi’s review of the Milan data on 2233 patients treated by 
quadrantectomy found that local recurrence rate at 10 years in those patients 
exhibiting lymphovascular invasion was 26% compared to 6% in the 
remaining patients (32). Although this difference appears striking, 
unfortunately the presence of lymphovascular invasion was not included in 
any subsequent analysis of the risk factors for local recurrence. Thus 
Veronesi’s results fail to shed any further light on the relationship between 
lymphovascular invasion and local recurrence.
The strongest data supporting the link between lymphovascular invasion and 
local recurrence has come from four separate studies (34,36,42-43). Sinn et al 
reviewed data on 957 patients treated by breast-conserving surgery of whom 
all the pathological data was reviewed independently (34). Among this cohort 
of patients, 203 (21%) had vascular invasion present (34). The presence of 
vascular invasion was found on a univariate analysis to be a strong predictor 
of local recurrence (34). When a multivariate analysis was performed vascular 
invasion remained a risk for the development of local recurrence, relative risk
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of 1.34 (34). Borger et al reviewed 969 patients treated by breast-conserving 
surgery (36). On performing a multivariate analysis lymphovascular invasion 
predicted for local recurrence (36). Similar results were found by Cowen et al 
(42). In the study by Finder et al a large cohort of 1704 women treated by 
breast-conserving surgery were followed up (43). The incidence of 
lymphovascular invasion was 22.8% (43). This group found that on a 
multivariate analysis lymphovascular invasion was a predictor of local 
recurrence, relative risk of 3.18 (43).
The above results have however been refuted by other studies (39-40), In the 
BORST trial, 7000 women treated by breast-conserving surgery throughout 
11 centres within the Netherlands were followed between 1980 and 1994 
(39). There were a total of 360 local recurrence (39). The presence of 
lymphovascular invasion was not found to be an independent predictor of 
local recurrence (39). Although the numbers of patients included within this 
trial are large, pathological data was only reviewed on a fraction of the total 
numbers. Among the local recurrences, in only 326 (91%) patients were 
pathological slides available (39). Furthermore, of the 6640 patients who did 
not develop local recurrence pathological data was reviewed on only 716 
(10.7%) of these patients (39). Thus the final statistical analysis was
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performed on a subgroup of the total numbers of patients thus biasing the final 
results.
In summary, there have been several studies that have shown a relationship 
between lymphovascular invasion and local recurrence. Although the presence 
of vascular invasion could be easily seen to predict for distal tumour spread, 
its association with local recurrence is more difficult to explain. The presence 
of tumour foci within blood vessels may be an indicator of wider local spread 
within the breast, thus reducing the effectiveness of wide local excision. This 
hypothesis seems to be backed by the data from the NSABP-B06 trial where 
the presence of lymphovascular invasion was a predictor of local recurrence 
among the patients treated by lumpectomy alone (38). This effect was negated 
however by the use of post-operative radiotherapy (38).
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Inflammatory response to tumour
The presence of an inflammatory infiltrate surrounding a breast cancer has 
occasionally been described by pathologists. There have however been 
relatively few studies analysing the relationship between this immunological 
reaction to the tumour and patient outcome, especially local recurrence. 
Lindey et al reviewed 293 patients with breast cancer treated by breast- 
conserving surgery (40). This team found that in their series there was a 12% 
incidence of a moderate or extensive chronic inflammatory response to the 
presence of tumour (40). The presence of this infiltrate was significantly 
associated with local recurrence, relative risk of 2.86 (40). In the Marseille 
trial the presence of a marked lymphocytic infiltration was also found on 
multivariate analysis to be a predictor of local recurrence (19). This 
relationship appeared to be independent of patient age (19). Similar results 
have been found by Kurtz et al (44).
Unfortunately, due to the relatively small numbers of patients demonstrating 
this reaction, the data available to date consists of few scanty reports 
involving a limited numbers of cases. Thus it is as yet not possible to 
determine confidently any possible relationship between this factor and local 
recurrence.
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Biological markers
The presence of oestrogen or progesterone receptor positivity in breast cancer 
is a valuable prognostic indicator. With the presence of oestrogen receptor 
positivity, the response to endocrine therapy can be expected in approximately 
60% of cases (45). This figure rises to 75% when both the oestrogen and 
progesterone rectors are positive (45), Despite the presence of routine testing 
for oestrogen receptor status over the past decade, there are very few studies 
dealing with the issue of whether oestrogen receptor status affects local 
recurrence. Furthermore, any such studies performed have shown conflicting 
results.
Yughan et al reviewed pathological data on 256 patients undergoing breast- 
conserving surgery and found that oestrogen receptor negativity was a 
predictor of local recurrence (46). This relationship remained significant after 
a multivariate analysis (46). This study does however have several limitations. 
Firstly the numbers of patients included within the study is relatively small. 
Furthermore, the local recurrence rate within this study was 27% which is 
significantly greater than most of the published data. This finding reflects the 
fact that patients included within this study were recruited between 1984 and 
1991 and over this period of time there would have been major changes in
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treatment protocols. This is confirmed by the fact that only 30% of patients 
received post-operative radiotherapy and this fact almost certainly would have 
biased Yaghan’s results. Vollenweider-Zerargini et al reviewed histological 
data on 547 patients in order to correlate receptor status with outcome (45). 
This team showed that oestrogen receptor positivity predicted for an improved 
disease-free survival (45). The presence of both oestrogen as well as 
progesterone positivity predicted for improved survival, however their 
presence did not predict for an improvement in disease-free survival (45). 
However, several studies have refuted these results (43,47-48).
Over the last decade there has been extensive research into the molecular 
biological characteristics of tumour that predict for relapse. Several factors 
have been identified as predictors of tumour recurrence. One such factor is Ki- 
67 (49). Aysegul et-al used anti Ki-67 antibodies and found that over­
expression of Ki-67 predicted for poorer tumour grade and younger age, both 
of which are recognised risk factors for local recurrence (50). Furthermore, 
several studies have found over-expression of Ki-67 to be a predictor of local 
recurrence (49-50). However, these studies are hampered by the fact that they 
include relatively small numbers of patients.
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Hartmann et al found in a study of 354 patients, that over-expression of the c- 
erb B2 oncogene resulted in a fall of the disease-free survival from 7.1 years 
to 2.9 years (51). Over-expression of c-erb B2 was also associated with 
axillary nodal disease, higher nuclear grade and oestrogen receptor negativity
(51). Similar results have been found by Seshadri et al (52). This team also 
found an association between c-erb B2 over-expression and a shorter time to 
recurrence of the breast cancer (52). When a multivariate analysis was 
performed however, over-expression of c-erb B2 oncogene was associated 
with a worse disease-free survival only in the presence of nodal positivity
(52). Gusterson et al showed on a study of 1506 patients that the absence of c- 
erb B2 expression was associated with a protective effect against tumour 
recurrence (relative risk of 0.57 in node positive and 0.82 in node negative 
patients) (53). It was also noted that over-expression of c-erb B2 was 
associated with a poorer response to the cyclophosphamide, methotrexate and 
5-flurouracil chemotheraputic regime (53). However, other researchers have 
found that among patients over expressing c-erb B2 the use of high dosage 
regimens including doxyrubacin can overcome this resistance (6). In summary 
the ability to measure specific gene products in breast cancer offers the 
potential to predict the biological behaviour of an individuals disease, thus 
allowing the specific targeting of adjuvant therapy.
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TREATMENT FACTORS
Inadequate surgical excision
One major risk factor for the development of local recurrence is believed to be 
the presence of residual disease left behind at the time of primary surgery. 
However despite the numbers of studies dealing with this subject, the analysis 
of their results is fraught with difficulty. This is partly due to the fact that in 
different studies varying techniques of surgical excision are employed. 
Furthermore, most of these studies have been performed over varying lengths 
of time. This invariably means that there have been differing adjuvant 
therapies available, which have an impact on the eventual results. Also, 
despite set protocols regarding surgical excision there is often no 
consideration of the impact of differences in inter-surgeon variation when the 
final analysis of these trials is performed.
Fisher et al showed that 86% of local recurrences occurred within the same 
quadrant as the primary tumour (54). Furthermore, these recurrences were of 
the same grade and histological type as the primary (54). Haffty et-al 
reviewed the results of 990 patients treated by breast-conserving surgery (55). 
This team showed that 57% of local recurrence were of the same pathological 
grade and type as well as within the same location within the breast as the
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primary tumour (55). However, when DNA flow cytometry was performed 
there was a poor correlation between the local recurrence and the primary 
tumour (55). This may be explained by the fact that there were only 33 
patients analysed by this technique. These small numbers of patients reduce 
the validity ofHaffly’s results. In the Milan trial, quadrantectomy was 
compared to a wide local excision of the tumour including a 1cm margin of 
grossly normal tissue (56). This study found that of those patients undergoing 
a wide local excision, 16% had positive resection margins compared to 3% of 
those undergoing quadantectomy (56). Furthermore, quadrantectomy was 
associated with lower local recurrence rates compared with more limited 
resection (reduction from 7% to 2.2%) (56). This clearly demonstrates the 
benefit achieved from more complete tumour resection.
The incidence of incomplete surgical excision of the breast primary is difficult 
to determine. The surgeon is often faced with a tumour that has a large and 
eccentric surface area. When this is combined with the fact that the tumour is 
often associated with irregular EIC extension, the possibility of inadequate 
tumour clearance exists. In the NSABP-06 trial the local recurrence rate was 
43% among patients undergoing wide-local excision but not receiving post­
operative radiotherapy (38). Holland et al showed that residual disease is 
found in 43% of cases (within a 2cm rim of grossly normal tissue surrounding
63
the tumour) (33). This figure approximates the local recurrence rate observed 
in the NSABP-B06 trial and indirectly contributes to the hypothesis that 
inadequate tumour excision predisposes to local recurrence. The problem of 
adequacy of tumour excision following breast-conserving surgery has led to 
various techniques that attempt to determine the completeness of tumour 
excision.
Several techniques have been described ranging fi'om assessment of the 
lumpectomy specimen margin either by inking or touch preparation cytology 
(57-58) to the use of cavity shaving biopsies. Assessment of tumour margin 
clearance by the India ink technique involves taking multiple sections fi'om the 
lumpectomy specimen and observing whether the tumour crosses or lies in 
close proximity to the inked margin. Unfortunately, there is no consensus 
regarding the definition of a positive tumour margin using this technique. 
Typically margin involvement is seen in 10% of cases (38). This value as 
demonstrated by Holland’s data is an underestimate of the extent of residual 
disease (33). Furthermore, there is often significant inter-observer variation 
seen in this technique as demonstrated by Fisher’s result where in only 31% of 
cases was there a consensus regarding positive margins between the hospital 
pathologist and the trials specialist pathologist (54). Furthermore, m a study 
by Schmidt-Ullrich et al between only 46-60% of patients undergoing a re-
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excision following a positive inked margin (defined as tumour less than 2mm 
from the inked margin) had disease within the re-excised specimen (59). Also, 
6% of patients had a re-excision because the tumour margin could not be 
assessed (59).
The method of touch preparation cytology has been described by Cox et al 
(57). Cox found that 18% of patients had a positive margin as assessed by this 
technique (57). In another study Cox showed that this technique was 
associated with 100% sensitivity and a 96.6% specificity (57). The advantage 
of this technique is that it takes approximately 15 minutes to obtain a result 
thus allowing a re-excision to be performed during the first operation, thus 
avoiding the need for re-hospitalisation. This technique does however have 
several limitations. Errors can occur due to specimen irregularity, diathermy 
artefact as well as diagnostic misinterpretation. More importantly false 
negative results have also been seen in tumours of special type for example 
lobular carcinoma (57).
The technique of cavity shavings involves excision of further tissue from the 
wall of the residual cavity following initial wide local excision. This tissue is 
subsequently analysed for the presence of residual disease (60-61). The 
method of taking a shaving of the residual cavity is a simple technique that is
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less laborious and allows assessment of the degree of residual invasive or in- 
situ disease. Macmillan et-al reviewed the results of 264 patients undergoing 
breast-conserving surgery and showed that residual invasive disease within 
the tumour bed was found in 39% of patients (61). This figure correlates well 
with Holland’s results (33). This group practised a policy of selective further 
surgery. In all 36 (13.6%) of patients underwent further surgery, 50% of 
whom had residual disease present within the re-excised tissue (61). This team 
found a local recurrence rate of 2% at mean follow-up of 4.4 years (61). This 
local recurrence rate is favourable when compared with the published 
literature (17,38,62-75). Guidi et al directly compared the techniques of inking 
and cavity shavings (60). In this study a total of 22 lumpectomy specimens 
were inked then a shaving from the surface of the inked margin was taken and 
analysed (60). From these 22 lumpectomies a total of 199 blocks were 
obtained (60). A total of 69 (34.7%) blocks showed a positive shaved margin 
(60). Of these only in 42 (61%) of cases was an inked margin present (60). 
This apparent discrepancy can be accounted for by the intrinsic differences in 
the two techniques. Inking involves selective evaluation of the surface of the 
specimen and in a large specimen this can be associated with a sampling error. 
The technique of cavity shaving however allows examination of a relatively 
large proportion of tissue surrounding the lumpectomy with relatively few 
histological sections. Furthermore, cavity shaving may also detect the
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presence of multifocal disease as well as inadequate excision thus explaining 
the greater incidence of detecting disease with the use of this technique.
In summary, several studies have shown that local recurrence commonly 
arises as a result of inadequate tumour excision. In order to assess the 
adequacy of tumour excision several techniques have been developed. All the 
techniques developed to date including cavity shavings and inking of margins 
have strengths as well as weaknesses. Commonly a positive inked margin is 
found in 10% of cases compared to tumour bed positivity being present in 
39% of cases. Among the institutions that routinely assess the tumour margin 
the presence of a positive margin invariably leads to further surgery. Thus not 
surprisingly there has as yet not been any direct statistical evidence linking a 
positive margin with local recurrence. However, of these institutions that have 
published their results, assessment of the tumour margin has resulted in a 
relatively low local recurrence rate (57,59,61).
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Post-operative radiotherapy
The use of ionising radiation in medical practice has been established since 
the late nineteenth century. It was not till the late 1950’s that the physiology 
of radiotherapy was better understood. Ionising radiation has both a direct 
effect on important molecular structures within tissues as well as an indirect 
effect where ionised radicals produced as a result of radiation cause damage 
to important biological structures.
With the advent of radiotherapy interest grew in less radical forms of surgery 
in order to reduce the extremely high rates of patient morbidity associated 
with more radical forms of surgery. An important breakthrough in the usage of 
radiotherapy came with the introduction of supravoltage radiation therapy 
equipment in the late 1950’s. This equipment allowed for the first time a 
homogenous dosage of radiation to the breast with minimal radiation scatter to 
the surrounding organs. With the availability of radioisotopes, such as 
Irridium-192 the use of a boost dose to a selected part of the breast became 
possible. More recently electron beam irradiation it has become possible to 
perform a boost dosage on a more convenient outpatient basis.
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The use of post-operative radiotherapy has been fundamental in the wider 
acceptance of breast-conserving surgery as a safe alternative to mastectomy. 
Several studies have shown the benefit of post-operative radiotherapy in 
reducing local recurrence (17,38,62-80). Some of this data is represented in 
Table 5 (17,38,62-64). As can be seen all these studies differ in design; 
patient population; follow-up; clinico-pathological patient factors as well as 
the extent of both surgical excision as well as radiotherapy regimens.
However despite these factors there is overwhelming evidence that supports 
the use of post-operative radiotherapy in reducing local recurrence following 
breast-conserving surgery.
One of the major European trails that analysed the efficacy of radiotherapy 
was published in the 1993 by Veronesi (17). In this trial 567 with cancers 
smaller that 2.5cm were randomised to quadrantectomy with or without post­
operative radiotherapy (17). The radiotherapy regime consisted of 50Gy to the 
whole breast over 5 weeks followed by a lOGy boost to the tumour bed (17). 
Veronesi found that those patients treated with radiotherapy had a low local 
recurrence rate of 0.3% compared to 17.5% for those who did not receive 
radiotherapy (17). In this study the primary surgery used was a 
quadrantectomy. This is more extensive than that used in most institutions. 
Thus Veronesi’s results may not reflect the data as a whole.
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There have been two major trials published from North America that have 
been influential in showing the benefits of post-operative radiotherapy. Fisher 
et al published the 10-year results of the NSABP-B06 trial in 1991(38). This 
trial consisted of 1857 patients with breast cancers, measuring 4cm or less, 
that were randomised to either mastectomy or lumpectomy alone or 
lumpectomy and post-operative radiotherapy (38). The local recurrence rate 
for those patients not receiving radiotherapy was 43% compared to 12% for 
those receiving post-operative radiotherapy (38). These results may have been 
biased by the fact that within this trial the post-operative radiotherapy regime 
consisted of 50Gy to the whole breast, however no boost dose was given to 
the breast (38). Several studies have shown that not providing a boost to the 
tumour bed is associated with poorer local control (81-82). Interestingly 
between year 1 to 3 of the follow-up the annual hazard rate of developing 
local recurrence in the lumpectomy alone cohort was 8.5% compared to 4.6% 
for years 4 to 10 of the follow-up period (38). This difference almost certainly 
represents inadequacy of tumour excision. There was no such variation seen in 
the radiotherapy cohort suggesting that radiotherapy is protective against 
residual disease.
In 1994 Whelan et al published the results from the other major North 
American trial (62). A total of 837 women with node negative breast cancer
70
were randomised into this trial (62). The local recurrence rate in the no 
treatment arm was significantly higher compared to those patients that 
received post-operative radiotherapy (30% versus 8%) (62).
Although there is a wealth of data proving the efficacy of post-operative 
radiotherapy in improving local control, there has been evidence however that 
the type of radiotherapy protocol may also have an influence outcome. 
Randomised trials have shown that not giving a booster dose to the tumour 
bed is associated with poorer local control (81-82). In a study by Romestaing 
et al, 1024 women with breast cancers were randomised after initial wide 
local excision and radiotherapy to the breast (50Gy) to receive an additional 
lOGy boost to the tumour bed (81). At a mean follow-up of 3.3 years the local 
recurrence rate within the boost cohort was 3.6% compared to 4.5% in the no 
boost cohort (81), Although this study contains a large number of patients the 
follow-up is relatively short and a longer follow-up would be required to 
ensure that this difference in the local recurrence rates is maintained over a 
longer period.
Deore et-al studied the effect of dose rate in post-operative radiotherapy on 
outcome in 270 patients (83). This team found that local recurrence was 
associated with implant dose rates less than 30 cGy/hr (83). It was also noted
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that increasing the implant dose rate greater than 100 cGy/hr was associated 
with a poorer cosmetic result (83). Other studies have found similar results 
(84-85).
Meek et al studied the impact of a delay in post-operative radiotherapy and its 
impact on local control (86). In this study a total of 300 patients were 
recruited between 1984 and 1989 (86). Of these, 247 patients underwent post­
operative radiotherapy with a mean delay of 8 weeks compared to 24 weeks 
in the “delayed” cohort. This delay was due to patients receiving adjuvant 
chemotherapy. Thus not surprisingly those patients who had delayed 
radiotherapy were younger and node positive compared to those patientsin 
whom radiotherapy was not delayed. Despite the differences in the clinico- 
pathological features between these two cohorts there was no significant 
difference in the local recurrence rate. This study however is limited by two 
factors, firstly the numbers included in this study are relatively small and 
secondly there has been no form of randomisation. Thus the results fiom this 
study are difficult to interpret. Leonard et al also analysed the relationship 
between a delay in post-operative radiotherapy and local control (87). In this 
study 262 patients were reviewed of whom in 105 patients radiotherapy was 
delayed due to chemotherapy (87). Leonard found that there was no 
significant difference in the local recurrence rate at 5-years between the two
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cohorts (87). Furthermore, there was no time interval between surgery and 
radiotherapy that affected the local recurrence rate (87). Unfortunately this 
study suffers from the same limitations as Meeks’s work. In order to analyse 
the effect of radiotherapy regimes on local recurrence there is the need for a 
meta-analysis.
In summary post-operative radiotherapy has been shown to have had an effect 
in reducing the local recurrence rates following breast-conserving surgery. 
This effect has been confirmed in meta-analysis of the published data (88). 
This publication by the “early breast cancer trialists’ collaborative group” 
reviewed the results of 36 trial containing a total of 17,273 patients (88). 
Radiotherapy was associated with a lower local recurrence rate (88). 
Interestingly radiotherapy had been shown to results in a fall in the breast- 
cancer-related deaths (88). This result has been reproduced by Haybittle et al 
(89). The fall in breast cancer-related deaths following post-operative 
radiotherapy may well represent the impact of a decrease in the local 
recurrence rate among those receiving radiotherapy.
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Table 5: Effect of post-operative radiotherapy on outcome 
following breast-conserving surgery
Trial N um ber
o f
patients
T um our
diam eter
(clinical)
T um our
excision
R egim en Follow -
up
(years)
Local
recurrence
rates
Significance  
(p-value)
M ilan III 579 <2.5 cm 2-3 cm 
grossly 
normal 
tissue
50 Gy 
plus 10 
Gy boost 
to
tumour
bed
4.4 8.8% N 
Vs
0.3% R
0.001*
N SA B P-
B 06
1843 < 4cm 1 cm gross 
&
pathologi­
cally clear
50 Gy 
No boost 
to
tumour
bed
9 43% N 
Vs
12% R
0.001*
Sw edish 381 < 2 cm 2 cm
pathologi­
cally clear
54 Gy 
No boost 
to
tumour
bed
5 18.4% N 
Vs
2.3% R
0.001*
Scottish 585 <4 cm 1 cm gross 
clearance
50 Gy 
10-15 Gy 
boost to 
tumour 
bed
6 28.6% N 
Vs
6.2% R
O C O G 799 < 4cm Grossly and 
pathologi­
cally clear
40 Gy 
and 12.5 
Gy boost 
to
tumour
bed
5 30% N 
Vs
8%R
<0.0001*
R= Postoperative radiotherapy performed 
N= No postoperative radiotherapy performed
Milan III: patients had quadrantectomy performed rather than a wide local excision 
* Values reach significance
74
Adjuvant therapy
The use of adjuvant in breast cancer has been established for a numbers of 
decades. Adjuvant therapy usually entails either hormonal manipulation, 
commonly through drugs the like of tamoxifen, or is in the form of 
chemotheraputic agents. Adjuvant therapy has primarily been used to improve 
outcome. However there is increasing evidence that adjuvant therapy may 
effect local control. Early indication of this effect was witnessed when 
patients with breast cancer treated primarily by adjuvant therapy rather than 
surgery showed shrinkage of the tumour within the breast. These results 
subsequently lead to the use of “neo-adjuvant” chemotherapy in order to 
shrink inoperable tumour thus allowing surgery to be performed. Although this 
technique involves treating patients aggressively prior to obtaining formal 
histology from the tumour or an axillary nodal status, thus running the risks of 
over treatment, the results so far have been encouraging (90-106). 
Cunningham et al reviewed data from 167 patients with clinical stage IIB,
IIIA or IIIB disease treated by neo-adjuvant chemotherapy (94). These 
patients were compared to 34 patients who received post-operative chemo- 
radiotherapy. Cunningham found that as well as allowing more limited 
surgery, neo-adjuvant therapy was associated with an improved overall 
survival (94). This difference did not however reach significance (94).
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Furthermore, there was no difference in the local recurrence rates between 
these two groups of patients (94). This study however has limited numbers of 
patients, which may be inadequate in number to detect a small but significant 
difference. Ferriere et al analysed the data from a cohort of 329 patients who 
were considered to have inoperable tumours (106). In this study in 85 (26%) 
patients the use of neo-adjuvant therapy allowed tumour shrinkage sufficient 
to enable a breast-conserving procedure to be performed (106). In a further 80 
(24%) patients there was complete clinical remission with these patients being 
subsequently treated by radiotherapy alone (106). However, an analysis of 
whether adjuvant therapy reduces local recurrence following surgery is more 
difficult to quantify. The effect of tumour-related characteristics as well as 
patient factors, all of which have a bearing on outcome, makes such studies 
difficult to perform.
Recent clinical trials suggest that the use of chemotherapy and tamoxifen 
either alone or in combination is associated with a reduction in both local 
recurrence and breast cancer-related death (107-113). However, in order to 
analyse any relationship between adjuvant therapy and local control studies 
containing large numbers of patients would be needed. There have however 
been two meta-analyses published that have analysed this specific subject 
(107-108). The “early breast cancer trialists’ collaborative group” published
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the results from a meta-analysis of the data from 75,000 women with breast 
cancer in 1992 (107), In a subgroup of 30,000 women results were available 
on the effect of tamoxifen on outcome (107). These patients were subdivided 
into those that were node positive or node negative (107). At 5-years those 
node negative patients receiving tamoxifen had an annual local recurrence rate 
of 3.62% compared to 5.22% among those not receiving tamoxifen (107). 
Similar results were found for the node positive cohort, 11.35% versus 
15.29% (107). This difference in local control was only observed for the first 
5 years after starting tamoxifen (107). Furthermore, although the presence of 
chemotherapy reduced the impact of tamoxifen’s protective effect on local 
control, this effect still remained significant despite the use of chemotherapy 
(107).
The effect of chemotherapy on local control was also analysed in the meta­
analysis by the “early breast cancer trialists’ collaborative group.” A total of 
11,000 women in 31 trials were randomised to poly-chemotherapy (107). 
Data was also present on a further 8000 women from 16 separate trials 
randomised to receive single agent versus no chemotherapy (107). The use of 
chemotherapy was associated with a reduction of local recurrence (107). Due 
to the heterogeneity of the chemotheraputic regimes the authors of this trial 
subdivided the data in order to allow a more informative analysis to be
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performed. When poly-chemotherapy regimes were compared with control the 
annual local recurrence rate fell from 15.12% to 10.96% (107). This 
protective effect against local recurrence was present among both node 
negative as well as node positive patients alike (107). This fall in local 
recurrence rate was only sustained for the first 5 years following surgery 
however (107).
The vast majority of poly-chemotheraputic regimens consisted of CMF. 
However, when regimes containing CMF in combination with other cytotoxic 
or hormonal agents were compared, the improvement in local control 
remained significantly better than among the control group of patients (107). 
Furthermore, the use of poly-chemotherapy appeared to better in preventing 
local recurrence than mono-chemotheraputic regimes (107). The duration of 
the chemotheraputic regimen also appeared to effect local control. The use of 
prolonged poly-chemotheraputic regimens appeared to be protective against 
local recurrence when compared to short term peri-operative regime (107).
This team also studied the impact of a range of immunotheraputic regimens on 
patient outcome. A total of 6300 women were randomised into 24 trials of 
immunotherapy (107). When performing the final analysis however the use of 
immunotherapy appeared to be associated with an increased local recurrence
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rate (107). This was especially the case among those women receiving BCG 
vaccination who had a significantly poorer local control compared to controls 
(107).
Clahsen et al performed a meta-analysis analysing the effect of a short course 
of poly-chemotherapy on patient outcome (108). This team reviewed the data 
on 6093 patients from 5 clinical trials (108). When this short course of poly­
chemotherapy was compared to controls, receiving chemotherapy resulted in a 
significant fall in the local recurrence rate (108). These results are m 
accordance with the early breast cancer trialists’ collaborative group’s results 
(107).
In summary the use of adjuvant therapy has been shown to be effective in 
helping reduce the incidence of local recurrence. This effect seems to be 
independent of axillary nodal status (107). However it is unclear whether such 
potentially toxic drugs should be used on node negative patients. This subject 
needs further evaluation.
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EFFECT OF LOCAL RECURRENCE ON SURVIVAL
The effect of local recurrence on patient survival is a matter of intense debate. 
Furthermore it is difficult to determine any such correlation. The risk factors 
such as tumour size, lymphovascular invasion and tumour grade and type that 
predict for local recurrence are also those risk factors predictive of systemic 
recurrence. This aligned to the fact that when considering the effect of local 
on systemic recurrence the impact of lead-time bias has to be taken into 
account makes any study setting out to determine such a correlation extremely 
difficult to design. Data collected from the NSABP-B06 trial has shown 
marked differences in the rates of local recurrence rates between those offered 
post-operative radiotherapy and those who were not (38). However, despite 
these differences in local recurrence rates, there was no significant difference 
in overall survival among the various treatment arms of this trial (38). This has 
led to the suggestion that there is no association between local recurrence and 
distant disease (114).
However, when patients who suffer a local recurrence are analysed as a 
separate population and outcomes assessed, it has been noted that the relative 
risk of developing systemic disease increases to between 1.2 to 6.6 (32,38). In 
the NSABP-B06 trial when a time dependent multivariate analysis was
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performed the presence of local recurrence was found to be a predictor of 
systemic recurrence, relative risk of 3.41 (38). Veronesi et al found similar 
results when they reviewed their experience of 2233 patients (32). In the 
NSABP-B06 trial it was shown that patients with local recurrence occurring 
within 1 year of the initial surgery had a higher incidence of systemic 
recurrence (38). Similarly, Veronesi showed the relative risk of developing 
systemic disease to be 6.6 if the local recurrence had occurred within one year 
of surgery (32). This risk fell to 2.2 and then to 1.2 for local recurrences 
occurring firstly 2 and then 3 years following surgery (32). Furthermore, 
analysis of results of the OCOG trial has shown that local recurrence is 
associated with poorer survival, relative risk being 2.18 (62). Similarly, 
Chauvet et al showed that the 5-year survival was 87.5% for those with local 
recurrence compared to 91.3% for those without (115). These results have 
been repeated in other studies (31,116-126).
Voogd et al analysed the pattern of relapse from the BORST trial and 
published results on 266 patients with local recurrence (119). This team found 
that patients with local recurrence suffered from poorer survival (119). 
However, the clinico-pathological characteristics of the local recurrence were 
also found to be predictors of poorer outcome. Patients presenting with 
palpable rather than mammographically detected recurrences had poorer
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survival (119). This finding reflects the fact that patients with larger 
recurrences have poorer outcomes in terms of survival (119). Furthermore, not 
surprisingly those patients with recurrences that were invasive rather than in- 
situ had a poorer survival (119).
Despite this wealth of data the numbers of local recurrences seen in each of 
the above studies is relatively small. Furthermore, all the above studies have 
taken place over a prolonged period of time during which there have 
invariably been changes in adjuvant therapy protocols offered to patients.
Such changes in themselves can have an impact on both local and systemic 
recurrence. Such variables have a detrimental effect on the power of the above 
studies to adequately assess any correlation between local and systemic 
recurrence. One possible method of counteracting these problems would be 
through the use of a meta-analysis technique.
In summary although breast-conserving surgery has gained in popularity the 
concerns about local recurrence and its effect on patient outcome remain. As 
yet although there is a wealth of evidence correlating local recurrence with 
poorer outcome, all these studies contain relatively small numbers of patients 
with local recurrence making such results difficult to interpret. Furthermore, 
none of the above studies have been able to explain the relationship between
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local failure and distal disease. One possibility is that local recurrence is an 
indicator of an aggressive disease process. The other possibility is that local 
recurrence causes systemic disease. In order to support a causal relationship 
between local and systemic recurrence there would be the need to 
demonstrate that by reducing the local recurrence rate a fall in systemic 
recurrence also occurs. To date there have been published several randomised 
trials demonstrating that post-operative radiotherapy results in a low local 
recurrence rate (17,38,62-64,76-80). However, in these trials there was no 
detected difference in overall survival among those patients not receiving 
radiotherapy. Despite the large numbers of patients included within these 
individual trials the numbers included may not be sufficient however to detect 
small difference in survival. In the meta-analysis by the “early breast cancer 
trialists’ collaborative group” however a fall in the breast cancer-related death 
rates among those receiving radiotherapy was seen (88). This finding suggests 
that there may well be a direct causal relationship between local and systemic 
recurrence (88). Despite this, as inadequate tumour excision is a major risk 
factor for the development of local recurrence, the importance of an adequate 
primary operation cannot be overestimated.
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MULTICENTRICITY OF BREAST CANCER
Several studies have shown that significant proportion of patients with breast 
cancer have multicentric disease (127-154). Vaidya et al showed that 
multicentric disease was present in 63% of patients (127). Furthermore, 
although the majority of primary tumours within this trial occurred in the 
upper outer quadrant of the breast, multicentric foci were distributed evenly 
throughout all quadrants of the breast (127). This group calculated that 
following a wide local excision of the primary tumour in 60% of cases 
residual multicentric foci would not have been excised (127). Furthermore, 
several researchers have found that in 50-62% of cases multicentric disease is 
genotypically different from the primary tumour (155-156). Other groups have 
found that histologically normal lobules surrounding the primary tumour 
express the same genotype as the cancer (157). All these results suggest that a 
significant proportion of patients undergoing breast-conserving surgery show a 
field change within the breast.
However, the majority of local recurrences occur close to the site of the 
previous operation or within the same quadrant as the primary (54). Thus, 
although the presence of multicentric disease within the breast is well 
recognised, it’s clinical significance remains uncertain. Megee et al showed
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that when radiotherapy to the whole breast was replaced by irradiation to the 
site of the tumour alone, the local recurrence rate rose from 13 to 25% (158). 
However, on closer inspection of this data, the increase in the local recurrence 
rate only occurred among patients with lobular carcinoma (158). Patients with 
invasive ductal carcinoma however showed a non-significant increase in the 
local recurrence rate from 11 to 15% (158).
In summary, although local recurrence is associated with inadequate tumour 
excision, the exact mechanism controlling the development of local recurrence 
is not completely understood.
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SUMMARY
Over the past decade breast-conserving surgery has become increasingly 
popular. Local recurrence however remains a contmuing problem however. 
Inadequate tumour excision has been shown to be one of the major risk 
factors for the development of local recurrence. Inking and tumour bed 
assessments are the two main techniques used to assess the adequacy of 
tumour excision. Previous studies have shown that tumour bed assessment is 
superior to inking in assessing the presence of residual disease.
The following thesis is an analysis of the experience of breast-conserving 
surgery at one institution over a period of 13 years. The majority of patients 
had tumour bed assessment performed. Six specific issues will be 
investigated:
1) Incidence of tumour bed positivity.
2) Correlation between clinico-pathological factors and tumour bed positivity.
3) Impact of tumour bed positivity on patient outcome.
4) Effect on the local recurrence rate of implementing a pragmatic policy of 
tumour bed assessment combined with selective re-excision.
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5) Correlation between pre-operative mammographie features and tumour bed 
positivity.
6) Correlation between tumour bed positivity and occult axillary disease.
The aim of this thesis is to expand upon the current knowledge in these 
specific areas in order to have a beneficial impact on clinical practice.
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CHAPTER 1 
INTRODUCTION
With the advent of radiotherapy surgical treatment of primary operable breast 
cancer by the use of breast-conserving surgery has become increasingly 
popular. A number of factors have influenced this change, the most important 
of which has been the publication of several clinical trials in the late 1980’s and 
early 1990’s that showed no survival advantage of mastectomy over breast- 
conserving surgery (15,16,31,38). The two major trials conducted over this 
period were by Veronesi in Milan and Fisher from the United States (15,38). 
Veronesi et al published results on 701 women between 1971 and 1980 with 
primary tumours of 2cm or less (15). In this trial conservation surgery consisted 
of a quadrantectomy and a level 3 axillary dissection (15). This Milan trial 
found no survival advantage of mastectomy over breast-conserving surgery 
(15). Fisher et al published the 10-year results of the NSABP-B06 trial in 1991 
(38). This team also found that the distant disease-free survival for those 
patients undergoing mastectomy was comparable to those undergoing a breast- 
conserving procedure (38).
The decision to offer breast-conserving surgery depends on several factors 
including tumour size; site and patient preference. The aim of breast-conserving
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surgery lies in providing an excellent cosmetic result while achieving local 
control. Local tumour recurrence following this form of surgery however 
remains a problem. Several studies have showed that local recurrence rates vary 
from 0.3 to 15% (17,38,62-64). There has been much debate about the impact 
of local recurrence on patient survival. Results from the NSABP-B06 trial have 
shown that although there was no difference in survival between those patients 
undergoing a mastectomy compared to breast-conserving surgery, among those 
patients who went on to develop local recurrence there was a strong association 
with subsequent systemic disease, relative risk of 3.41 (38). Similarly results 
from the OCOG trial randomising 837 patients to radiotherapy following initial 
breast-conserving surgery found that local recurrence was associated with an 
increased risk of subsequent systemic recurrence, relative risk of 2.11 (62).
Thus although breast-conserving surgery has become widely accepted, the 
importance of achieving a low local recurrence rate cannot be underestimated.
The literature is awash with analyses of the risk factors for local recurrence 
following breast-conserving surgery (17,32,38,62-64,76-80). Recognised risk 
factors include poorer tumour grade; extensive in-situ disease within the tumour 
and lymphovascular invasion. The major risk factor for developing local 
recurrence however is inadequate tumour excision. Due to the fact that patients 
with a positive margin invariably undergo further surgery, a direct association 
between positive margins and local recurrence has been difficult to identify in
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the published literature. However the study by Holland et al does provide 
indirect evidence of a link between positive margins and local recurrence (33). 
In this study a total of 282 mastectomy specimens from patients thought to be 
suitable for breast-conserving surgery were sectioned (33). Holland et al found 
that within a 2cm rim of grossly normal tissue surrounding the tumour, residual 
disease was present in 43% of cases (33). This figure is similar to the local 
recurrence rate seen in the NSABP-B06 trial among patients not receiving post­
operative radiotherapy (38). A number of different factors make the 
completeness of surgical excision difficult to determine however. Firstly 
lumpectomy specimens usually have a large and irregular surface area, 
containing a non-uniform tumour, thus making analysis difficult. Furthermore, 
the pathologist commonly has to deal with specimens containing eccentric 
intraductal tumour extension (159), All these problems make gross assessment 
of tumour margin unreliable.
Attempts have been made to determine the adequacy of tumour clearance more 
precisely. The two methods commonly used to determine tumour clearance are 
India ink staining of the lumpectomy specimen and pathological assessment of 
shavings from the residual cavity following initial wide local excision. 
Assessment of the tumour margin using the India ink staining involves the 
pathologist dipping the specimen in ink followed by taking random biopsies 
from the surface of the specimen in order to detect whether the tumour lies
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“close” to or actually crosses this inked margin. This technique of tumour 
margin assessment was used in both the Milan and the NSABP-B06 trials 
(17,38). Unfortunately within the literature there is no consensus regarding a 
positive inked margin. Typically margin involvement is found in 10% of cases 
(38). However if Holland’s results are taken into account then this figure 
underestimates the extent of residual disease (33). Furthermore, Frazier et al 
found that in patients undergoing a re-excision after a negative inked margin 
residual disease was present in 30% of cases (160). Thus the main concern 
about the technique of inking is that it may be underestimating the incidence of 
positive margins.
An alternative approach to the problem of assessing completeness of excision is 
to analyse what is left in the breast rather than what is at the surface of the 
excised specimen. The technique of cavity wall shaving has previously been 
described (61). Macmillan et al reviewed 264 patients undergoing breast- 
conserving surgery, all of whom had tumour bed assessment performed (61). In 
this study the incidence of residual disease within the tumour bed was 39.3% 
(61). In 51.5% of cases this disease was purely in-situ in nature (61). This 
institution performed a policy of selective surgery, either mastectomy or re­
excision, for those patients with positive cavity shavings. Of the patients with a 
positive margin, 36 (35.6%) underwent further surgery of whom 50% had 
evidence of residual disease (61). This study does however have several
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limitations. Firstly due to the retrospective nature of the study the cohort of 
patients is relatively small and non-randomised. This weakens any subsequent 
statistical analysis. Furthermore the policy of this unit about proceeding for 
further surgery does not seem to be uniform in nature. Of the patients with a 
positive margin only 35.6% underwent further surgery. This may well reflect a 
change in clinical practice over the period of this study, however not comment 
on this fact is made by the authors. In order analyse the efficacy of tumour bed 
assessment in detecting residual disease as well as having an impact on 
lowering the local recurrence rate a much larger study with longer follow-up 
would be needed.
Beck et al performed a prospective study on 144 patients directly comparing 
cavity shavings with inking of margins (162). In this study all patients 
underwent a wide local excision followed by biopsies of the superior, inferior, 
medial and lateral walls of the residual cavity. Following this, formal cavity 
shavings were performed (162). The lumpectomy specimen was subsequently 
fixed and inked (162). Beck et al found that in 43% of cases there was evidence 
of a positive margin detected by all three methods (162). Both tumour bed 
assessment and inking detected a positive margin in 27% of the cases compared 
to only 17% for bed biopsy (162). The incidence of positive bed biopsy seen in 
this study seems to be less than that of 25% reported in the literature however 
(163). Interestingly although both inking and cavity shavings detected a
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positive margin in 27% of cases, in only 63% of these cases was there 
concordance between both these techniques (162). This suggests that the 
presence of a positive inked margin is a poor predictor of residual disease as 
assessed by cavity shavings. The finding of a clear inked margin in the presence 
of disease within the cavity shavings is of clinical concern. This discrepancy 
may be explained by the fact that tumour bed assessment as well as detecting 
residual disease also detects foci of disease distant from the primary and thus 
has an inherently better detection rate than the technique of inking.
In summary breast-conserving surgery has been shown to be a safe alternative 
to mastectomy. However, local recurrence remains a continuing problem. One 
of the major risk factors for the development of local recurrence is inadequate 
tumour excision. Several techniques to assess the tumour margin have been 
developed. The use of tumour bed assessment appears to detect a higher 
incidence of positive margins compared to inking. The aim of this study is to 
expand upon previous work correlating clinico-pathological factors that predict 
for tumour bed positivity as well as ascertaining the overall incidence of tumour 
bed positivity. Furthermore, the effect of tumour bed positivity on patient 
outcome will also be analysed.
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PATIENTS AND METHODS
Patients
A total of 752 patients entered the study between September 1982 and 
December 1995. All had stage I or II breast cancer. Of these, a total of 543 
(72%) patients had cavity shavings performed following initial wide local 
excision. Patients in whom cavity shavings were not performed were operated 
upon prior to December 1987. The mean age of patient was 54.88 years (range 
21-84, S.D. 10.38 years. Graph I.l).
Four hundred and eighty four (64%) patients presented symptomatically and 
112 (15%) patients had screen-detected palpable tumours, while 156 (21%) 
patients had screen-detected impalpable tumours. Symptomatic patients 
presenting to out-patient clinics had a preoperative diagnosis made by a 
combination of clinical assessment, mammography (both cranio-caudal and 
oblique views performed) and fine needle aspiration (FNA) cytology and/or tru- 
cut biopsy.
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Graph 1.1: Distribution of patients’ age at diagnosis
2  20
21 30  3 7  4 3  4 9  5 5  61 6 7  73  79
27  3 4  4 0  4 6  52  58  6 4  70  7 6  82
Age at diagnosis
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Surgical technique
All patients underwent a wide local excision with a l-2cm macroscopic 
clearance. The deep margin of excision was the pectoralis fascia. Wherever 
necessary, a skin ellipse overlying the tumour was excised encompassing the 
fine needle aspiration/tru-cut biopsy site or areas of skin tethering. With the 
introduction of tumour bed assessment from 1988 onwards, following initial 
wide local excision, tissue forceps were applied to the wall of the residual 
cavity and a thin shaving of tissue was excised (cavity shavings)(Illustration 
1.1). This tissue was submitted separately for histopathological analysis.
Of patients that attended via the National Health Service Breast Screening 
Programme (NHSBSP) with impalpable lesions, if a pre-operative core biopsy 
had been obtained by ultrasound or stereotaxis, definitive surgery was 
subsequently performed. Otherwise, a diagnostic biopsy was followed by 
definitive surgery. In all, 85% of patients had a level II axillary clearance 
performed.
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Illustration 1.1: Technique of performing cavity shavings
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Pathological assessment
All tissue submitted was assessed in the pathology department of the Western 
Infirmary, Glasgow and assessed by a pathologist specialising in breast disease. 
The maximum tumour and lumpectomy diameters as well as tumour grade 
(Bloom and Richardson) were recorded (163). The presence of an intraduct 
component within the tumour was also noted and classified as being absent, 
minimal or extensive in nature. Where commented on by the pathologist, the 
presence of lymphovascular invasion, neural invasion or a lymphocyte infiltrate 
surrounding the tumour were also recorded. Tissue was also analysed for 
oestrogen receptor status. This analysis was initially performed biochemically, 
however from the early 1990’s the use of immunohistochemical techniques 
were increasingly applied. Thus for the purposes of this study the oestrogen 
receptor status was recorded as being positive or negative rather than as a 
continuous variable.
The cavity shavings were blocked, sectioned and examined for the presence of 
invasive and/or in-situ disease. The total number of blocks of tissue processed 
from the cavity shavings varied from 4 to 54. The number of foci of disease 
within the cavity shavings, as well as the number of blocks involved with 
disease, were also recorded.
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Adjuvant therapy
In general, patients who had axillary nodal disease received adjuvant systemic 
therapy. This was in the form of tamoxifen and chemotherapy, either given 
alone or in combination. If patients were oestrogen receptor positive they were 
offered tamoxifen at the dose of 20mg per day. If however, they fell into a poor 
prognostic category as assessed by the Nottingham Prognostic Index (164) they 
were offered chemotherapy consisting in the majority of cases of 6 pulses of 
cyclophosphamide, methotrexate and 5-flurouracil. A total of 529 (70.3%) 
patients received tamoxifen and 98 (13%) patients received adjuvant 
chemotherapy. In all, 551 (73.3%) patients received post-operative radiotherapy 
to the breast consisting of 46 Gy in 23 fractions over 35 days with a 12 Gy 
boost to the tumour bed in 4 fractions over 7 days. Of the 201 patients not 
receiving adjuvant radiotherapy, in 57 (28.3%) cases this was due to the fact 
that these patients went on to have a mastectomy following initial attempts at 
breast-conserving surgery. The remaining 144 (71.7%) of these patients were 
those entered into clinical trials and randomised to not receive radiotherapy.
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Statistical analysis
Statistical analysis was performed using a SPSS (version 7.51) statistics 
package. This allowed the calculation of simple frequencies and percentages 
from the available data. More complex statistical analyses were needed in order 
to correlate tumour bed positivity with established clinico-pathological 
prognostic factors. In this situation a Pearson’s chi-squared test was used to 
calculate significance. Factors assessed included mode of presentation as well 
as tumour pathological factors. The Pearson’s chi-squared test was also used to 
compare the sociological distribution of this cohort of patients with the national 
average. A comparison of mode of presentation as well as the Nottingham 
Prognostic Index (164) with deprivation category was also performed. When a 
comparison of means was required the Independent sample t-test was used.
This was used to compare patient age with tumour bed positivity. A Mann- 
Whitney test was used to compare lumpectomy and tumour diameters with 
tumour bed positivity. In order to perform a multivariate analysis of the factors 
that predict for tumour bed positivity a stepwise Logistic Regression analysis 
was performed. A 5% significance level was used throughout this analysis.
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In order to assess the effect of cavity shaving positivity on patient outcome, at 
the end of the period of follow-up, three measures of outcome were assessed:
1: Disease-free survival (DFS): defined as those patients who are alive and 
well and not having sustained a local recurrence, contralateral breast tumour, 
axillary recurrence or systemic recurrence.
2: Distant disease-free survival (DDFS): defined as those patients being free 
of systemic disease and not dying from breast cancer.
3: Overall survival (OS): defined as those patients not dying from breast 
cancer.
Survival curves were calculated using the Kaplan-Meier technique. In order to 
compare the effect of tumour bed positivity on DFS, DDFS and OS the log- 
rank test was performed. The log-rank test was also used to analyse any 
relationship between tumour bed positivity and local recurrence. Multivariate 
analyses using the Cox proportional hazard model (165) were used to produce a 
set of in-depth useful predictions of survival. The model was performed in a 
stepwise manner with only the co-variâtes reaching a 5% significance level 
being included in the final model. The co-variâtes included in the model were 
age at diagnosis, maximum tumour diameter (pathological), tumour grade, 
axillary nodal status and oestrogen receptor status.
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RESULTS
Socio-economic grouping
The Western Infirmary, Glasgow is a tertiary referral centre for breast cancer in 
the West of Scotland. This is reflected in the patient population, where 47.8% 
of the 575 of patients on whom postcode information was available, lived out 
side Glasgow.
In order to gain a better understanding of the socio-economic distribution of 
this group of patients we correlated postcode data with deprivation category 
information supplied by Glasgow University/ A breakdown of these results 
and comparison to the expected national average is represented in Table 1.1. As 
can be seen from these results, there is a greater than expected representation 
from deprivation category ranges 1-2 and 6-7 among the Western Infirmary 
patients than the expected national average. A Pearson’s chi-squared test 
however showed no statistically significant difference between the two 
populations, p=0.099.
Deprivation category data was also compared with mode of presentation. A 
similar analysis as to the above was performed. When patients in deprivation 
categories 1-2 and 6-7 were compared although there were differences between
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observed and expected outcomes as for mode of presentation, these were not 
statistically significant (Table 1.2). The Nottingham Prognostic Index (164), 
which was calculated on 570 patients, was compared with deprivation category 
data. When a Pearson’s chi-squared test was performed there was no significant 
association between poorer deprivation category and a poorer Nottingham 
Prognostic Index.
* Deprivation category is used by sociologists in order to categorise people living in certain 
postcode areas of the country into various socio-economic groups. Deprivation category 1 or 2 
refers to people living in affluent areas where as categories 6 or 7 refers to deprived areas of the 
country.
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Table 1.1: Deprivation category
D eprivation category  
range
W estern Infirm ary data  
(% )
Expected Scottish  
average (% )
1-2 30.3 24.2
3-5 45.2 59.7
6-7 24.5 16.1
Comparison between Western Infirmary patients and the Scottish average as for deprivation category 
ranges.
Table 1.2: Presentation versus deprivation category
D eprivation category Sym ptom atic
presentation
Screen-detected  
(im palpable tum our)
O bserved
count
E xpected
count
O bserved
count
Expected
count
1-2 91 94.5 44 40.5
6-7 94 81 27 35
Comparison o f mode of presentation, either symptomatic or screen-detected non-palpable tumours, 
with deprivation category range.
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Operative pathology
In all, 631 (84%) patients presented with invasive ductal carcinoma, whereas 49 
(6.5%) patients had lobular carcinoma and 72 (9.5%) patients presented with 
tumours of special type. The mean tumour diameter was 13.79 mm. 
Furthermore, the mean tumour diameter for symptomatic patients was 
16.10mm compared to 13.19mm for those patients with screen-detected yet 
palpable tumours,/?<0.0001.
A level II axillary clearance was performed on 643 (85%) patients. In 617 of 
these patients, data on number of positive nodes as well as the total number of 
nodes retrieved was available. Information on axillary node positivity is 
presented in Table 1.3. The mean number of nodes retrieved was 11 (range 2- 
30) with a total of 179 (29%) of these patients being node-positive.
Table 1.3: Lymph node positivity
N um ber o f  cases P ercentage
N ode negative 438 71
1-3 136 22
4-10 34 5.5
>10 9 1.5
T otal num ber o f  cases 617 100
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Tumour bed positivity
Cavity shavings were performed in order to ascertain tumour margin clearance 
in a total of 543 (72%) patients. Based on the type and extent of disease, a 
proportion of patients underwent further surgery - either re-excision or 
mastectomy. The decision to offer further surgical intervention was a pragmatic 
one and depended on the type and extent of disease. Patients with extensive 
invasive and/or in-situ disease involving most of the cavity shavings underwent 
a mastectomy. Those patients with minimal to moderate invasive and/or in-situ 
disease - for example 1 focus of invasive disease in one block combined with 
in-situ disease within three to four blocks had a re-excision performed. In those 
patients with very minimal disease -  for example one to three foci of in-situ 
disease limited to one block had no further surgery (Illustration 1.2).
A total of 200 (37%) patients were tumour bed positive. Of these, 26 (13%) 
patients had a re-excision performed. When the re-excised tissue was examined 
histologically, 11 (37.9%) patients had residual invasive or in-situ disease. In a 
further 57 (29%) patients a mastectomy was performed. In this subgroup of 
patients, 17 (30%) patients had residual invasive or in-situ disease within the 
masteetomy specimen. Of the 117 (58%) patients who were tumour bed 
positive but did not undergo further surgery all had between 1 to 3 foci of
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disease confined to one block of tissue. Patients who underwent mastectomy 
were subsequently excluded from the majority of the following analyses.
Of the 486 breast-conserved patients a total of 143 (29.4%) patients had 
residual disease in the cavity shavings, Table 1.4. The presence of disease 
varied from a single focus of DCIS in 1 block to invasive disease present within 
several blocks.
Although the total number of blocks of tissue processed from the cavity 
shavings varied from 4 to 54, there was no association between tumour bed 
positivity and the number of blocks processed from the cavity shavings, 
p-Q.Q15,
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Illustration 1.2: Flow chart representing further surgical
intervention
Total number of patients (543)
Tumour bed positive (200) Tumour bed negative (343)
Mastectomy (57) Re-excision (26)
Total breast-conserved (486)
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Table 1.4: Incidence of tumour bed positivity
T ype o f  disease present N um ber o f  cases Percentage o f  
total num ber o f  cases
Invasive carcinom a (or  
m ixed invasive/in-situ  
disease)
51 10.5
In-situ disease 92 18.9
T otal positive 143 29.4
T otal negative 343 70.6
T otal num ber o f  cases 486 100
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Effect o f patient age on tumour bed positivity
The relationship between patient age at diagnosis and tumour bed positivity 
was examined using an independent sample t-test. The mean age of tumour bed 
positive patients was 54 years compared to 56 years for tumour bed negative 
patients, p~0.064.
Effect o f clinical presentation
The relationship between mode of clinical presentation and the incidence as 
well as type of disease within the cavity shavings is represented in Tables 1.5- 
1.6. Patients presenting symptomatically had an increased incidence of tumour 
bed positivity when compared with screen-detected patients, /i=0.042.
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Table 1.5: Clinical presentation and tumour bed positivity
M ode o f  
presentation
C avity  shavings  
positive
C avity  shavings  
negative
T otal num ber o f
cases
Sym ptom atic 91 (33)* 184 (67) 275
Screen-detected  
palpable tum ours
14 (18) 62 (82) 76
Screen-detected
im palpable
tum ours
38 (28) 97 (72) 135
* p = 0 .0 4 2
Table 1.6: Clinical presentation and type of tumour bed 
disease
M ode o f  
presentation
Invasive (or m ixed
invasive/in -situ
disease)
In-situ  disease T otal num ber o f
cases
Sym ptom atic 35 (38) 56 (62) 91
Screen-detected  
palpable tum ours
4 (29) 10 (71) 14
Screen-detected
im palpable
tum ours
................... ...  ..
12 (32) 26 (68) 38
Values in parentheses are percentages
in
Effect o f extent of excision
Tumour diameter ranged from 5 to 35 mm (mean 13.55mm, S.D.
6.60mm). The mean tumour diameter for tumour bed positive patients 
was 14.41mm compared to 13.20mm for tumour bed negative patients,
/)=0.068. Furthermore, the mean lumpectomy diameter for tumour bed 
positive patients was 59mm compared with 63mm for tumour bed 
negative patients, p=0.075.
Overall, 468 patients had the tumour diameter recorded. In order to assess the 
effect of both tumour diameter and lumpectomy diameter on tumour bed 
positivity, the lumpectomy diameter was tabulated against cavity shaving status 
for a range of tumour diameters. The Mann-Whitney test was used to detect 
any underlying associations. These results are represented in Table 1.7. For 
patients with tumour diameters of 21-30mm, the mean lumpectomy diameter of 
the tumour bed positive group was significantly smaller than the tumour bed 
negative group, p=0.029.
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Table 1.7: Relationship between tumour/ lumpectomy 
diameter and tumour bed positivity
M ean lum pectom y diam eter (m m )
T um our
diam eter
C avity shavings  
positive
C avity  shavings  
negative
Total num ber o f  
cases
Significance
(p-value)
<10m m 55.7 59.9 199 0.052
ll-2 0 m m 61.6 64 228 0.691
21-30m m 65.6 76.5 37 0.029
>30m m 0 83.7 4 Not calculable
Effect o f tumour pathological factors
The relationship between tumour pathological factors and tumour bed 
positivity is represented in Tables 1.8-1.15. Tumour bed positivity was 
significantly associated with tumour grade II, /?=0.0001. When the 
Mental-Haenszel chi-squared test was performed there was an 
association between poorer tumour grade and tumour bed positivity, 
p=0.042. The presence of lympho vascular invasion was associated 
with the presence of invasive disease within the cavity shavings,
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p=0.021. An extensive in-situ component within the tumour was 
associated with both tumour bed positivity and the presence of in-situ 
disease within the cavity shavings,/;=0.002 and 0.010 respectively. 
Conversely, oestrogen receptor positivity was found to be associated 
with tumour bed positivity, />=0,045.
Effect o f axillary nodal status
The relationship between tumour bed positivity and axillary nodal 
disease is represented in Tables 1.16-1.17. There was a significant 
relationship between invasive (or mixed invasive/ in-situ) disease in 
the cavity shavings and axillary nodal disease, /i=0.009. There was 
also a trend towards the presence of invasive disease within the cavity 
shavings and an increasing number of positive nodes, p=0.007.
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Table 1.8: Tumour grade and tumour bed positivity
Tumour grade Cavity shavings 
positive
Cavity shavings 
negative
Total number o f
cases
Grade I 21 (20) 84 (80) 105
Grade II 92 (42)* 125 (58) 217
Grade III 14 (19) 61 (81) 75
Not defined 16 (18) 73 (82) 89
*p=0.0001
Table 1.9: Tumour grade and type of tumour bed disease
Tumour grade Invasive (or mixed
invasive/in-situ
disease)
In-situ disease Total number o f
cases
Grade I 8(38) 13 (62) 21
Grade II 28 (30) 64 (70) 92
Grade III 6(43) 8(57) 14
Not defined 9(56) 7 (44) 16
•  Values in parentheses are percentages
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Table 1.10: Lymphovaseular invasion and tumour bed positivity
Lymphovaseular 
invasion present
Total number of 
cases
Cavity shavings 
positive
25 (17) 143
Cavity shavings 
negative
53 (15) 343
Table 1.11: Lymphovaseular invasion and type of tumour bed 
disease
Invasive (or mixed
invasive/in-situ
disease)
In-situ disease Total number o f  
cases
Lymphovaseular 
invasion present
14 (56)* 11 (44) 25
*p=0.021
•  Values in parentheses are percentages
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Table 1.12: Tumour in-situ component and tumour bed 
positivity
Type of in-situ 
disease within 
tumour
Cavity shavings 
positive
Cavity shavings 
negative
Total number o f  
cases
Extensive in-situ 
disease
90 (36)* 158 (64) 248
Minimal in-situ 
disease
20 (27) 53 (73) 73
Absence o f in-situ 
disease
33 (20) 132 (80) 165
*p=0.002
Table 1.13: Tumour in-situ component and type of tumour bed 
disease
Type o f in-situ 
disease within 
tumour
Invasive (or mixed
invasive/in-situ
disease)
In-situ disease Total number 
o f cases
Extensive in-situ 
disease
28 (31) 62 (69)* 90
Minimal in-situ 
disease
8(40) 12(60) 1 20
Absence o f  in-situ 
disease
15 (45) 18(55) 33
*p=0.01
• Values in parentheses are percentages
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Table 1.14: Oestrogen receptor status and tumour bed positivity
Cavity shavings 
positive
Cavity shavings 
negative
Total number o f  
cases
Oestrogen receptor 
positive
104 (32)* 225 (68) 329
Oestrogen receptor 
negative
25 (22) 90 (78) 115
*p= 0 .045
Table 1.15: Oestrogen receptor status and type of tumour bed 
disease
Invasive (or mixed
invasive/in-situ
disease)
In-situ disease Total number
o f cases
Oestrogen receptor 
positive
38 (37) 66 (63) 104
Oestrogen receptor 
negative
11 (44) 14 (56) 25
Values in parentheses are percentages
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Table 1.16: Nodal status and tumour bed positivity
Axillary nodal 
status
Cavity shavings 
positive
Cavity shavings 
negative
Total number 
of cases
Node negative 89 (27) 235 (73) 324
1-3 nodes 
positive
30 (36) 53 (64) 83
> 3 nodes 
positive
6 (33) 12 (67) 18
Table 1.17: Nodal status and tumour bed disease
Axillary nodal 
status
Invasive (or 
mixed invasive/in- 
situ disease)
In-situ disease Total number
o f cases
Node negative 26 (29) 63 (71) 89
Node positive 19 (53)* 17 (47) 36
1-3 nodes 
positive
15 (50) 15(50) 30
> 3 nodes 
positive
4 (67) 2 (33) 6
* p=0.009
• Values in parentheses are pereentages
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Multivariate analysis o f predictors o f tumour bed positivity
A multivariate analysis of all the factors which predicted for tumour bed 
positivity was performed, Table 1.18. On performing this analysis only poorer 
tumour grade; extensive in-situ disease within the tumour and axillary nodal 
disease predicted for tumour bed positivity.
Table 1.18: Multivariate analysis of predictors of tumour bed 
positivity
F actor Significance (p- 
value)
R elative risk 95%  C onfidence  
interval
Sym ptom atic
presentation
0.2078 0.7627 0.4724-1.2314
O estrogen receptor  
positivity
0.0505 0.6068 0.3678-1.0012
L ym phovasu lar
invasion
0.1178 0.6975 0.4441-1.0955
P oorer tum our  
grade
0.0457* 2.5992 1.0186-6.6327
A xillary nodal 
disease
0.0002 0.4390 0.2838-0.6791
E xtensive in-situ  
disease w ith in  the  
tum our
0.0236 0.5952 0.3798-0.9328
Comparing grade II and III with grade I patients.
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Effect of tumour bed positivity on patient outcome
Patients were followed-up at a 3 monthly interval at outpatient clinics during 
the first 5 years following surgery and then at 6 monthly intervals thereafter. 
The mean follow-up was 52 months (range 14-105 months). Patient outcomes 
are presented in Table 1.19.
Table 1.19: Patient outcomes
Patient outcom es C avity  shavings positive C avity shavings negative
Local
recurrence
4 (2.8) 7 (2 )
A xillary
recurrence
5 (3.5) 1 (0.3)
C ontralateral breast 
cancer
3 (2 ) 4 (1 )
A live w ith system ic  
recurrence
6 (4 ) 6 (1 .7 )
B reast eancer-related  
death
1 3 (9 ) 16 (4.7)
N on-breast cancer- 
related death
15(10 .5 ) 5 (1.5)
Total num ber  
o f  cases
143 343
Values in parentheses are percentages
121
Probability o f Disease-Free Survival (DFS)
The linear representation of DFS for the cavity shavings positive and negative 
cohorts is shown in Graph 1.2. On performing the log-rank test, tumour bed 
positive patients had a poorer DFS, />=0.0445. When the effect of tumour bed 
positivity on local recurrence was examined however, there was no evidence of 
an association between disease within the tumour bed and local recurrence, 
p=Q.19A\ (log-rank test).
On performing a Cox regression analysis of all the co-variates, only oestrogen 
receptor negativity and axillary nodal disease predicted for poorer DFS, 
/>=0.0062 and 0.0061 respectively (Table 1.20). These co-variates were then 
entered into the final model which demonstrated that the presence of disease 
within the cavity shavings was a predictor of poorer DFS,/?=0.0140 (relative 
risk 2.0803, 95% confidence interval 1.1595-3.7325).
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Graph 1.2: Linear representation of Disease-Free Survival (DFS)
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Table 1.20: Cox regression analysis of Disease-Free
Survival (DFS)
C o-variate Significance
(p-value)
R elative risk 95%  C onfidence interval
A ge at 
diagnosis
0 3 8 1 1 0.9879 0.9614-1.0151
M axim um  tum our  
diam eter
0.4808 1.0161 0.9719-1.0624
Poorer tum our  
grade
0.1142 1.2869 0.9411-1.7597
A xillary nodal 
disease
0.0061 1.6135 0.9769-1.0669
O estrogen receptor  
negativity
0.0062 2.4065 1.2834-4.5125
T um our bed 
positivity
0.0140 2.0803 1.1595-3.7325
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Probability of Distant Disease-Free Survival (DDFS)
The linear representation of DDFS for the cavity shavings positive and negative 
cohorts is shown in Graph 1.3. On performing the log-rank test, the tumour bed 
positive patients had a poorer DDFS, p-0.0092.
On performing a Cox regression analysis of all the co-variates, only oestrogen 
receptor negativity and axillary nodal disease predicted for poorer DDFS, 
p=0.0003 and 0.0118 respectively (Table 1.21). These co-variates were then 
entered into the final model which demonstrated that the presence of disease 
within the cavity shavings was a predictor of poorer DDFS, /?=0.0010 (relative 
risk 3.2754, 95% confidence interval 1.6122-6.6544).
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Graph 1.3: Linear representation of incidence of Distant
Disease-Free Survival (DDFS)
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Table 1.21: Cox regression analysis of Distant Disease-Free
Survival (DDFS)
C o-variate Significance
(p-value)
R elative risk 95%  C onfidence interval
A ge at 
diagnosis
0.7631 1.0045 0.9756-1.0342
M axim um  tum our  
diam eter
0.3347 1.0189 0.9809-1.0584
Poorer tum our  
grade
0.9272 1.0145 0.7446-1.3823
A xillary nodal 
disease
0.0118 1.0962 1.0206-1.1775
O estrogen receptor  
negativity
0.0003 3.2724 1.7333-6.1783
T um our bed  
positivity
0.0010 3.2754 1.16122-6.6544
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Probability o f Overall Survival (OS)
The linear representation of overall survival for the cavity shavings positive and 
negative cohorts is shown in Graph 1.4. On performing the log-rank test, there 
was no significant difference between the tumour bed positive and negative 
patients, p=0.1210.
When cavity shaving status was tabulated against nodal disease, node 
negative/tumour bed positive patients did worse than tumour bed negative/node 
negative patients (Graph 1.5). However, this difference was not significant, 
/7=0.2303.
On performing a Cox regression analysis of all the co-variates, only axillary 
nodal disease predicted for poorer overall survival,/?=0.0092 (Table 1.22). This 
co-variate was then entered into the final model which demonstrated that the 
presence of cavity shaving disease did not predict for poorer overall survival, 
/?-0.1030.
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Graph 1.4: Linear representation of incidence of Overall
Survival (OS)
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Graph 1.5: Linear representation of incidence of Overall 
Survival (OS), tabulating cavity shaving (CS) status 
against nodal disease
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Table 1-22: Cox regression analysis of Overall Survival (OS)
C o-variate Significance
(p-value)
R elative risk 95%  C onfidence in terval
A ge at 
diagnosis
0.1754 1.0249 0.9891-1.0620
M axim um  tum our  
diam eter
0.1849 1.0363 0.9831-1.0924
P oorer tum our  
grade
0.2045 1.2858 0.8720-1.8960
A xillary nodal 
disease
0.0092 1.8173 1.1595-2.8481
O estrogen receptor  
negativity
0.2794 1.5610 0.6966-3.4979
T um our bed  
positivity
0.1030 1.3332 0.9436-1.8836
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Effect o f extensive tumour bed disease on patient outcome
In all, 57 (10.5%) patients underwent a mastectomy due to extensive residual 
disease within the tumour bed. Of these patients in 36 (63%) cases this disease 
was invasive (or mixed invasive/in-situ disease) in nature. Graphs 1.6-1.7 
represent the effect on DFS and overall survival of a patient undergoing further 
surgery, either mastectomy or re-excision.
Of note is the fact that patients undergoing further surgery for residual disease 
had a poorer DFS and overall survival than those patients who were tumour bed 
positive but did not undergo further surgery. When the log-rank test was 
performed however, this difference did not reach significance,/?=0,5207 and 
0.4605 respectively.
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Graph 1.6: Effect of further surgery on Disease-Free 
Survival (DFS)
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Graph 1.7: Effect of further surgery on Overall Survival (OS)
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Effect o f adjuvant therapy on outcome
Of the 543 patients who had tumour bed assessment performed 441 (81.2%) 
had post-operative radiotherapy. Of the 102 (18.2%) of patients who did not 
receive radiotherapy, 57 (10.5%) underwent a mastectomy and a further 45 
(7.7%) were entered into clinical trials. A further 431 (79.4%) of patients were 
offered tamoxifen and 61 (11.2%) were offered adjuvant chemotherapy.
On performing the log-rank test, patients receiving post-operative radiotherapy 
were found to have a slightly better overall survival,/i==0.0193 (Graph 1.8). 
However, receiving post-operative radiotherapy was not found to be beneficial 
on either DFS or DDFS,/;=0.6055 and 0.7652 respectively. There was no 
association between adjuvant chemotherapy and improved DFS, DDFS or 
overall survival,/?=0.4942, 0.9975 and 0.1841 respectively. Furthermore, 
receiving tamoxifen was not associated with an obvious improvement in either 
DFS, DDFS or overall survival,/?=0.1206, 0.9448 and 0.5207 respectively.
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Graph 1.8: Effect of radiotherapy on Overall Survival (OS)
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DISCUSSION
Breast-conserving surgery has become an increasing popular alternative to 
mastectomy over the last decade. Although several trials have shown that 
breast-conserving surgery is associated with equivalent rates of survival 
compared with mastectomy, the problem of local recurrence persists. The major 
risk factor for the development of local recurrence is inadequate tumour 
excision. In order to facilitate an improved assessment of the tumour margin 
following lumpectomy, several techniques have been developed. Assessment of 
the tumour bed has been shown to be more effective at detecting residual 
disease than the inking of margins (38,61,162). A previous publication from 
this institution showed the incidence of tumour bed positivity to be 39.3% (61).
In order to update and re-analyse earlier results we proceeded to undertake this 
retrospective analysis of this institutions experience in breast-conserving 
surgery over the previous 15 years. This study addresses three main issues 
firstly, the incidence of residual disease within the tumour bed after breast- 
conserving surgery; secondly risk factors associated with tumour bed positivity 
and thirdly the association between tumour bed positivity and patient outcome. 
Although the Western Infirmary in Glasgow is a tertiary referral centre no 
significant difference in the socio-ecenomic distribution of this cohort of 
patients when compared to the Scottish average was noted.
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Among the 543 patients that had cavity shavings performed the incidence of 
tumour bed positivity was 37%. This figure correlates well with the previously 
published data (61). In the initial study from this institution by Macmillan et al 
the only clinico-pathological factor that predicted for tumour bed positivity was 
poorer tumour grade (61). The results from this study however show that 
tumour bed positivity is associated with symptomatic presentation; poorer 
tumour grade; lymphovascular invasion; axillary nodal disease and EIC. 
Furthermore, when a multivariate analysis is performed poorer tumour grade; 
axillary nodal disease and extensive in-situ disease within the breast are all 
predictors of tumour bed positivitry. There may be several factors responsible 
for this difference in results between these two studies. Firstly, the original 
study contained only 264 patients. Thus the increase in the numbers of patients 
analysed in the present study may have resulted in detection of associations that 
previously did not reach significance. Furthermore, Macmillan’s data is 
gathered retrospectively from 1988 to 1992. Thus this data may also have 
suffered from inter-observer variation in pathological reporting as only latterly 
was there a specialist pathologist reporting on all breast cases. One weakness in 
the current study however is the fact that the histological slides were not 
reviewed. Thus for some of the earlier patients included in this study a 
specialist pathologist may not have reported the pathological slides raising the 
possibility of inaccuracy. Despite this misgiving the current study has shown 
several clinico-pathological features that predict for a positive tumour margin.
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Furthermore, all the risk factors for tumour bed positivity have also been 
previously shown to be independent risk factors for the development of local 
recurrence (17,31,32,34-38,42). This raises the possibility that the presence of 
poorer tumour grade; lymphovascular invasion and extensive in-situ disease 
within the tumour may be markers of a more locally advanced disease process 
within the breast. Consequently in such cases a traditional wide local excision 
may leave behind residual disease that can eventually progress on to a local 
recurrence.
In this study there was an association between residual invasive disease within 
the cavity shavings and axillary nodal disease. This result may be due to the 
fact that invasive disease within the cavity shavings was associated with the 
presence of lymphovascular invasion. The presence of lymphovascular invasion 
has previously been found to be a predictor of nodal disease and poorer survival 
(28,30,32,34,36). This result may however be biased by the sampling error 
introduced, as results on axillary nodal status were not present in all the patients 
who underwent axillary clearance.
The finding that oestrogen receptor positivity predicted for disease within the 
tumour bed was unexpected and may be due to a disproportionately high 
incidence of oestrogen receptor positivity within this group of patients. This
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apparent association did not however reach significance when a multivariate 
analysis is performed.
In this institution a policy of selective further surgery has been employed when 
dealing with positive tumour margins. The decision whether to perform further 
surgery has always been a pragmatic one. Several factors determine whether 
patients proceed to re-excision or mastectomy following initial wide local 
excision. These factors include patient choice; general fitness for further 
surgical intervention as well as both the type and extent of residual disease 
within the tumour bed. A total of 42% of the patients with tumour bed 
positivity underwent further surgery, either re-excision or mastectomy. Among 
the remaining 58% of patients not undergoing further surgery, all had between 
1 to 3 foci of disease confined to one block of tissue from the cavity shavings. 
Of the patients undergoing further surgery residual disease was found in 33.7% 
of cases. Although these results suggest that a proportion of patients underwent 
unnecessary procedures, it is not always possible to sample a mastectomy 
specimen extensively, thus the presence of residual disease can be 
underestimated. Furthermore, the approach used within this institution is one of 
prevention. Interestingly in the earlier study by Macmillan et al only 35.6% of 
patients with a positive margin underwent frirther surgery compared to 42% in 
this updated series. This suggests that there has been a gradual change with 
time towards further surgery if a positive tumour margin is present.
140
In this study an overall local recurrence rate of 2.3% was observed. This is low 
when compared with the published data (38,62-64). There was no association 
between tumour bed positivity and local recurrence. The fact that tumour bed 
positivity is not a predictor of local recurrence is not surprising as those patients 
who have extensive disease within the tumour bed often undergo further 
surgery in order to clear this disease. Thus they can subsequently be regarded as 
being at a low risk of developing local recurrence.
The systemic recurrence rate in this series was only 2.5%, which is low 
compared to the published literature (17,31-32,38,56,62-64,162). This may 
however be accounted by the fact that in the literature the incidence of nodal 
positivity varies from 33% to 43% (31-32,56,162). In this series however only 
29% of the patients had nodal disease. Thus this population may well be 
skewed towards a better outcome. The increased incidence of non-breast 
cancer-related deaths seen in the tumour bed positive cohort is a quandary. This 
may well represent differences in cardiovascular risk factors within this cohort 
of patients that are out with the scope of this study.
Tumour bed positivity was found to predict for poorer DFS and DDFS but not 
overall survival. The lack of a relationship between tumour bed positivity and 
overall survival may however be due to the length of follow-up. With a longer 
follow-up such a relationship may become apparent. It should be noted that due
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to the low local recurrence rate observed, the impact of tumour bed positivity 
on DFS is due mainly to its effect on systemic recurrence. Although no formal 
analysis of the impact of local recurrence on patient outcome was performed 
within this study, it is interesting to note that a positive tumour margin that is a 
predictor of the adequacy of tumour excision and thus local control, can also 
have an impact on systemic recurrence. This suggests that there may be a 
relationship between local and systemic disease. Evidence from the literature 
seems to back this hypothesis. Results from the NSABP-B06 trial have shown 
that those patients who go on to develop local recurrence have a strong 
association with subsequent systemic disease, relative risk of 3.41 (38).
Similarly results have been found in the OCOG trial, relative risk of 2.11 (62). 
Interestingly, patients undergoing further surgery for extensive residual disease 
within the tumour bed have been found to have poorer DFS and overall survival 
than those tumour bed positive patients who did not merit further surgery. The 
effect on poorer survival of tumour bed positivity thus seems to be independent 
of any residual disease within the breast itself. This suggests that those patients 
who have extensive residual disease at the onset form a subgroup of patients 
who have aggressive cancers.
When assessing the effect of adjuvant therapy on outcome it was found that the 
use of tamoxifen was associated with an improvement in DFS. Furthermore, 
there was no association between DFS and post-operative radiotherapy. These
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results highlight the fact that due to the low local recurrence rate the major 
impact on DFS is from systemic recurrence.
In summary, the use of cavity shavings is a simple and efficient method of 
assessing the tumour margin. This technique detects a high incidence of occult 
disease within the tumour bed. Furthermore, the local recurrence rate observed 
in this series is favourable, when compared to the published literature.
However, the results from this study suggests that adoption of a policy of 
selective further surgery in order to achieve a low local recurrence rate comes 
at the expense of a high a re-excision or mastectomy rate. This policy can result 
in excess morbidity. Furthermore, patients with extensive disease within the 
tumour bed form a subgroup who have been shown to have poorer outcome and 
in whom more radical surgery may not be justified. In order to clarify the 
relationship between tumour bed positivity and local recurrence further 
prospective study randomising patients with tumour bed positivity to further 
and no further surgery may well be needed. Such a study would confirm any 
link between residual disease within the tumour bed and local recurrence thus 
allowing justification of pursuing an aggressive policy of re-excision.
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CHAPTER 2 
INTRODUCTION
The aim of breast-conserving surgery in the treatment of breast cancer is 
to excise the tumour completely and achieve an excellent cosmetic result. 
This must not however compromise the degree of local control allowed 
by mastectomy. The decision to opt for breast-conserving surgery is 
based on several factors including tumour size; site and patient 
preference. The consequences of inappropriately selecting patients for 
breast-conserving surgery are re-operation (re-excision or mastectomy) in 
order to obtain disease-free excision margins or at worst, local recurrence. 
Data obtained from prospective randomised trials has shown that the 
incidence of local recurrence varies from 0.3 to 15% in patients receiving 
post-operative radiotherapy and increases up to 43% in those not 
receiving post-operative radiotherapy (17,38,62-64). The significance of 
local recurrence following breast-conserving surgery and its relationship 
to long term outcome is however the subject of debate.
The risk factors for the development of local recurrence have previously 
been reviewed (22,166). However, inadequate tumour excision has been 
recognised as a major risk for the development of local recurrence
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(22,166). In order to ensure adequacy of tumour clearance, several groups 
advocate inking of the specimen with India ink (17,38,167). This method 
of tumour margin assessment is laborious and involves taking multiple 
sections from the excision specimen in order to assess whether the 
tumour crosses or lies “close” to the inked margin. Also, only a small 
proportion of the excision specimen surface area can be assessed by this 
method. Furthermore, there is no consensus regarding a positive tumour 
margin using this technique. An alternative approach to assess the 
completeness of excision is to look for the presence of residual disease 
within the breast. The technique of tumour bed assessment involves the 
histopathological analysis of shavings from the residual cavity following 
wide local excision of the primary tumour. The techniques of margin 
inking and tumour bed assessment are not however wholly compatible, as 
tumour bed assessment will detect residual disease as well as isolated foci 
of disease distant from the tumour. Inking has been shown to 
underestimate the extent of residual disease as assessed by analysing the 
tumour bed (60,162).
Taylor et al reviewed 286 patients who had the tumour margin assessed 
by performing bed biopsy from the walls of the residual cavity (163). 
Taylor found that in 22% of cases there was evidence of a positive margin 
(163). Furthermore, tumour bed positivity was found to predict for local
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recurrence (163). Assersohn et al however found no association between 
involved margins and local recurrence (166). In this study a cohort of 
only 184 patients was analysed and this number may be inadequate to 
detect any association between positive margins and local recurrence. 
Furthermore, in this study margins were assessed by inking, a technique 
that has been shown to underestimate the extent of residual disease 
(60,162). This fact may also have influenced Aeeersohn’s results.
In summary inadequate tumour excision has been shown to be a major 
risk factor for the development of local recurrence following breast- 
conserving surgery. Several techniques have been devised to assess the 
adequacy of tumour excision. However, tumour bed assessment has been 
shown to detect a higher incidence of residual disease when compared to 
inking of margins (60,162). Prior to 1988 in this institution there was no 
formal policy of margin analysis. From 1988 onwards however, all 
patients undergoing breast-conserving surgery had tumour bed 
assessment performed. The aim of this study is to assess the impact of 
adopting tumour bed assessment combined with a pragmatic policy of 
selective re-excision on the local recurrence rate. In order to achieve this 
patients treated pre-1988 were compared with patients treated post-1988, 
with all patients having a fixed follow-up period.
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PATIENTS AND METHODS
Patients
A total of 364 patients were treated by breast-conserving surgery between 
September 1982 and June 1992. All had stage I or II breast cancer, 
diagnosed by triple assessment. The mean age of patients was 55years 
(range 26-81, SD. 10.68 years). All 125 patients treated prior to 1988 
presented symptomatically. Of the 239 patients treated post-1988, 136 
(56.9%) patients presented symptomatically and the remaining 103 
(43.1%) were referred through the National Health Service Breast 
Screening Programme (NHSBSP).
Surgical technique
The surgical technique has already been described in chapter one. In all 
patients, the surgeon performed a macroscopic resection of the tumour. 
From 1988 onwards however, following initial wide local excision, tissue 
forceps were applied to the wall of the residual cavity and a thin shaving 
of tissue excised (cavity shavings). This was submitted separately for 
histopathological analysis. All the cavity shavings were serially blocked, 
sectioned and analysed.
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Further surgery
From 1988 onwards, based on tumour bed positivity, a proportion of 
patients underwent re-excision. The decision to offer further surgical 
intervention was a pragmatic one and depended on the type and extent of 
disease.
The incidence of tumour bed positivity was 30.5% (73/239 patients). A 
total of 12/73 (16.4%) patients underwent re-excision in light of tumour 
bed positivity. Of the 61/73 tumour bed positive patients who did not 
undergo further surgery, all had between 1 and 3 foci of disease, which 
were confined to one block of the cavity shavings. In 59/61 of these 
patients the disease was in-situ in nature. In the 2 cases where the disease 
was invasive, it was restricted to 1 focus of disease in one block.
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Adjuvant therapy
In all, 289 (79.3%) patients received post-operative radiotherapy to the 
breast consisting of 46 Gy in 23 fractions over 35 days with a 12 Gy 
boost to the tumour bed in 4 fractions over 7 days. The majority of 
patients who did not receive radiotherapy were those entered into clinical 
trials and randomised not to receive post-operative radiotherapy. A total 
of 42 (11.5%) patients received adjuvant chemotherapy and 235 (64.5%) 
patients received tamoxifen (Table 2.1).
Table 2.1: Adjuvant therapy
A d juvan t therapy P re-1988 group (% ) Post-1988 group (% )
R adiotherapy 103 (82.4) 186 (77.8)
C hem otherapy 27 (21.6) 15 (6.3)
T am oxifen 52 (41.6) 183 (76.6)
T otal 125 239
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Follow-up
In order to obtain a full five-year follow-up for both cohorts, patients 
were followed up prospectively at outpatient clinics. All patients were 
seen regularly at three monthly intervals for the first year and six monthly 
intervals thereafter. Two-view mammography was performed every two 
years. During the five-year follow-up period of this study 4 patients were 
lost to follow-up in the pre-1988 group and 2 patients in the post-1988 
group. All patients lost to follow-up were well at the last clinic visit. In 
order to obtain a meaningful comparison between these two cohorts of 
patients, all events occurring at a fixed  five-year follow-up period in each 
individual patient was documented.
Statistical analysis
The Pearson's chi-squared test and the independent sample t-test were 
used to assess differences in clinico-pathological factors between the pre- 
and post-1988 cohorts. A 5% significance level was used in this analysis.
The Kaplan-Meier technique was used to produce a curve of the 
incidence of local recurrence. The log-rank test was performed in order to
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determine underlying differences in the incidence of local recurrence 
between the groups of patients.
Multivariate analyses using the Cox proportional hazard model (165) was 
used to produce a set of in-depth useful predictions of local recurrence. 
The model was performed in a stepwise manner with only co-variates 
reaching a 5% significance level being included in the final model. The 
same co-variates as in chapter one were included in the model.
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RESULTS
In the pre-1988 non-cavity shavings group the mean age at diagnosis was 
55.16 years (S.D=12.06 years) compared with 55.11 years (S.D=10.05 
years) in the post-1988 cavity shavings group,/?=0.93. In all, 296 (81%) 
patients presented with invasive ductal carcinoma, 20 (5.5%) with lobular 
carcinoma, 27 (7.5%) with tumours of special type and in the remaining 
21 (6%) the type of tumour was not defined. Oestrogen receptor status 
was determined on 302 patients. Of these, 204 (67.5%) patients were 
oestrogen receptor positive. A total of 304 (83.5%) patients underwent 
axillary surgery (level II clearance) and of these 33% had nodal disease.
Results of patient pathology and any underlying significant associations 
are presented in Table 2.2. There were more patients in the post-1988 
group with smaller, node-negative tumours than in the pre-1988 group. 
This difference is probably due to the influence of the NHSBSP. Also of 
note was the apparent increased incidence of oestrogen receptor positivity 
seen in the post-1988 group. This may be spurious in that only 82/125 
(65.6%) patient pre 1988 had receptor status determined compared with 
204/239 (85.3%) patients in the post-1988 group.
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Table 2.2: Comparison of pathological factors between pre-
and post-1988 groups
Pathological factors Pre-1988 group (% ) Post-1988 group (% )
D u cta l carcinom a 85 (68) 211 (88.3)
L ob u lar carcinom a 8 (6.4) 12 (5)
Special type 11 (8.8) 16 (6.7)
N ot defined 21 (16.8) 0
M ean tum our d iam eter (m m ) 19 13 p=0.0001
O estrogen receptor positive 41/82 (50) 163/220 (74) p=0.0001
N ode positive 39/97* (40.2) 60/204 (29.4) p =0.007
T otal 125 239
* Pathological results of nodal status were available in 97 of the 100 patients who 
had axillary surgery in the pre-1988 group.
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Patient outcome
Patient outcome at the end of follow-up is shown in Table 2.3. As can be 
seen the incidence of local recurrence fell from 15.7% pre-1988 to 2.5% 
post-1988. The linear representation of local recurrence is shown in 
Graph 2.1. On performing the log-rank test, the difference in the local 
recurrence rates between these two groups of patients is significant, 
p<0.00001. Also of note, is that in the pre-1988 group 32% of the local 
recurrences occurred within 1 year of surgery.
A Cox regression analysis was performed with only oestrogen receptor 
negativity predicting for local recurrence,/?=0.012 (Table 2.4). This co- 
variate was entered into the final model. On performing the final model, 
the pre 1988 group of patients had significantly poorer local recurrence 
rates, /?=0.0002 (relative risk 8.0832, 95% confidence interval 2.7249- 
23.9777).
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Table 2.3: Outcomes after fixed 5 year follow-up in the pre
and post-1988 groups
O utcom e P re-1988 group (% ) P ost-1988 group (% )
L ocal
recurrence
19 (15.7) 6 (2.5)
C ontralateral breast 
tum our
4 (3.3) 1 (0.4)
A xillary recurrence 2 (1.6) 2 (0.8)
A live w ith  system ic  
recurrence
9 (7.4) 5 (2.1)
B reast cancer-related  
death
14 (11.6) 18 (7.6)
N on-breast cancer- 
related death
3 (2.5) 10 (4.2)
T otal 121 237
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Graph 2.1: Incidence of local recurrence
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Table 2.4: Cox regression analysis of local recurrence
C o-variate Significance
(p-value)
R elative
risk
95%  C onfidence interval
A ge at 
diagnosis
0.1660 0.9631 0.9131-1.0157
M axim um  tum our  
diam eter
0.9830 0.9991 0.9223-1.0824
Poorer tum our  
grade
0.5764 1.1781 0.6629-2.0937
A xillary nodal 
disease
0.9167 0.9876 0.7811-1.2485
O estrogen receptor  
negativity
0.0120 2.7989 1.2539-6.2476
Pre-1988
group
0.0002 8.0832 2.7249-23.9777
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Effect o f adjuvant therapy on local recurrence
In all, 79.3% of patients received post-operative radiotherapy; 11.5% of 
patients received adjuvant chemotherapy and 64.5% of patients received 
tamoxifen. The log-rank test v^as used to assess any relationship between 
adjuvant therapy and local recurrence.
On performing the log-rank test patients who did not receive adjuvant 
chemotherapy or tamoxifen had an increased incidence of local 
recurrence, /?=0.003 and 0.0002 respectively. There was however no 
association found between those who did not receive post-operative 
radiotherapy and an increased incidence of local recurrence,/>=0.4666.
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DISCUSSION
Although breast-conserving surgery has been shown to be a safe 
alternative to mastectomy local recurrence remains a persisting problem. 
Development of local recurrence has both psychological effects on patient 
morale as well as effecting patient outcome. Of the risk factors for the 
development of local recurrence inadequate tumour excision remains 
paramount. There are several recognised techniques used to determine 
adequacy of tumour excision. Tumour bed assessment has been shown to 
detect a high incidence of disease within the tumour bed (60,61,161-163). 
Furthermore, tumour bed assessment can provide an indication of those 
patients at risk of developing local recurrence. Preliminary data from this 
institution has shown that the combination of tumour bed assessment with 
selective further surgery resulted in a low local recurrence rate (61).
The current study examines the impact of the introduction of a policy of 
tumour bed assessment in 1988, on local recurrence. In order to achieve 
this goal data on patients treated pre-1988 was reviewed and compared to 
the post-1988 results, with all patients having a fixed 5-year follow up. 
Patients were recruited into this study from 1982 to 1992. In 1987 breast 
screening was introduced and the combination of this with the fact that 
these two cohorts were not randomised explains the fact that there were
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more patients in the post-1988 group with smaller, node-negative tumours 
than in the pre-1988 group. Furthermore, there are marked differences in 
the use of adjuvant therapy, especially chemotherapy and tamoxifen 
between these two groups of patients. These represent changes in clinical 
practice as well as differences in clinico-pathological features between 
these two heterogeneous groups of patients.
The incidence of tumour bed positivity seen in the post-1988 group was 
30.5%. This is less that that of 39.3% previously reported by Macmillan 
et al (61). One explanation for this may be the difference between these 
two studies in the numbers of patients analysed. Of the patients with a 
positive margin 16.4% underwent frirther re-excision for extensive 
disease within the tumour bed. The remaining patients with a positive 
margin who did not undergo further surgery all had between 1 to 3 foci 
disease confined to one block of the cavity shavings. In these patients due 
to the minimal nature of disease present within the tumour bed a clinical 
decision was made not to undertake further surgery. Macmillan showed 
that 35.6% of patients with a positive margin underwent further surgery 
(61). In the current study the rate of further surgery is almost half of that 
reported in Macmillan’s study. The explanation for this apparent 
difference is that Macmillan’s data included 29 patients that underwent a 
mastectomy for extensive disease within the tumour bed. However, the
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aim of the current study is to analyse local recurrence, thus patients with 
mastectomy were excluded from the data. However, the rate of re­
excision seen in Macmillan’s data and the current study are comparable.
The local recurrence rate seen in the post-1988 group is consistent with 
previously published results (61). A significant fall in the local recurrence 
rate pre- to post-1988 was observed however. This fall in local recurrence 
may be due to an improvement in the adequacy of local tumour excision 
provided by tumour bed assessment. However, these results may be 
influenced by differences in clinico-pathological factors as well as 
adjuvant therapy between these two groups of patients. There were 
significantly more patients in the pre-1988 group that had larger tumour 
that were node positive and tended to be oestrogen receptor negative. 
Oestrogen receptor negativity has been shown to be a risk fact for local 
recurrence (45,46). A similar result has been found in this study. Also, 
larger tumour diameter has been shown to be a risk for local recurrence in 
both the Milan and the NSABP-B06 trials (32,16). Furthermore, 
differences in the extent of local surgical excision practised prior to 1988 
may also have influenced the relatively high local recurrence rate 
witnessed prior to 1988. This is indicated by the fact that 32% of the local 
recurrences pre-1988 occurred within 1 year of surgery confirming 
inadequate tumour excision as being a major factor.
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There were significant differences in adjuvant therapy between the pre- 
and post-1988 group of patients. In the pre-1988 group 82.4% of patients 
received post-operative radiotherapy compared to 77.8% in the post-1988 
group. This variation between these two groups is due to a difference in 
the number of patients being entered into clinical trials and being 
randomised not to receive radiotherapy. Furthermore, there was no 
change in the radiotherapy regime over the time frame of this study. Thus 
differences in the numbers receiving post-operative radiotherapy between 
these two groups are unlikely to have had an impact on changes in the 
local recurrence rate that have been witnessed.
Only 41.6% of the pre-1988 group of patients received tamoxifen 
compared to 76.6% of patients post-1988. This represents a change in 
clinical practice occurring between pre- and post-1988. This may also 
have influenced the results. On performing a univariate analysis it was 
found that patients who did not receive tamoxifen had an increased risk of 
local recurrence. This result concurs with the literature. The “early breast 
cancer trialists’ collaborative group” published the results from a meta­
analysis of the data from 75,000 women with breast cancer (107). This 
team found that at 5-years follow-up, node negative patients receiving 
tamoxifen had an annual local recurrence rate of 3.62% compared to 
5.22% among those not receiving tamoxifen (107). Similar results were
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found for the node positive patients, 11.35% versus 15.29% (107). This 
benefit to local control was only observed for the first 5 years after 
starting tamoxifen (107).
Adjuvant chemotherapy was used in 21.6% of patients pre-1988 
compared to only 6.3% of patients post-1988. This is almost certainly due 
to the fact that the pre-1988 group consisted of patients with larger often 
oestrogen receptor negative and node positive patients. The higher 
incidence of systemic recurrence and breast cancer-related death seen in 
the pre-1988 group of patients reflects this. Furthermore, the results from 
this study show that chemotherapy had a protective effect against local 
recurrence. This finding concurs with the results from a meta-analysis of 
11,000 women with breast cancer randomised to poly-chemotherapy from 
31 trials (107). In this study data was also present on a further 8000 
women from 16 separate trials randomised to receive single agent versus 
no chemotherapy (107). The study found that the use of chemotherapy 
was associated with a protective effect against local recurrence (107).
In summary this study has shown that tumour bed assessment detects a 
high incidence of occult disease within the breast. Furthermore, the 
combination of tumour bed assessment with selective further surgery may 
have resulted in a fall in the local recurrence rate witnessed post-1988.
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However, due to the retrospective, non-randomised design of this study 
the pre- and post-1988 groups of patients are heterogeneous nature. 
Subsequently the fall in local recurrence is multifactorial in origin. It may 
be accounted by the impact of tumour bed assessment resulting in an 
improvement in the adequacy of tumour excision. However differences in 
clinico-pathological features as well as adjuvant therapy between the pre- 
and post-1988 groups almost certainly had an influence on local 
recurrence. In order to analyse this subject further there needs to be 
performed a prospective trial where patients are randomised to either 
tumour bed assessment or no formal margin analysis. However, as 
adequacy of tumour excision has been shown to be a major risk for the 
development of local recurrence such a study would raise ethical 
concerns.
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CHAPTER 3 
INTRODUCTION
Over the past decade breast-conserving surgery has become an 
increasingly popular alternative to mastectomy in the management of 
operable breast cancer. However, local recurrence remains a persistent 
problem. Clinico-pathological factors recognised as predictors for the 
development of local recurrence include inadequate tumour excision; 
extensive in-situ disease within the tumour (EIC); poorer tumour grade 
and the presence of lymphovascular invasion. It is vital to select only 
those patients appropriate for breast-conserving surgery, as inappropriate 
patient selection is associated with the morbidity entailed with further 
surgical procedures in order to ensure adequacy of tumour clearance. The 
factors commonly used in determining a patient’s suitability for breast- 
conserving surgery are patient choice as well as the clinical size and 
location of the tumour within the breast. Mammography is an essential 
tool in the pre-operative assessment of patients undergoing surgery for 
breast cancer. In addition to revealing diagnostic radiological 
abnormalities, pre-operative mammographie features may also determine 
those patients that should be suitable for breast-conserving surgery. 
Several studies have found a correlation between pre-operative
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mammographie features and clinico-pathological risk factors for the 
development of local recurrence (169-177). These results have the 
potential in aiding the clinician in selecting those patients that are suitable 
for breast-conserving surgery.
Healey et al analysed the results of pre-operative mammograms from 101 
patients undergoing breast-conserving surgery (169). Within this group,
41 (40.5%) patients showed evidence of EIC (169). The presence of EIC 
has been shown to be an independent risk factor for the development of 
local recurrence (34,37). Healey et al found that EIC was associated with 
the presence of microcalcification as well as an absence of a 
mammographie nidus (169). Furthermore, when Stomper et al reviewed 
the results of 101 pre-operative mammograms, the presence of 
mammographie microcalcification measuring greater than 3 cm in 
diameter was also associated with EIC (170).
There have also been several studies published looking at the relationship 
between mammographie features and the incidence of positive margins 
following breast-conserving surgery (171-175). Unfortunately some of 
these studies contain small numbers of patients making interpretation of 
the results limited (171-172). Morrow et al however published the results 
of 263 patients with stage I and II breast cancer that were suitable for
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breast-conserving surgery (173). Morrow found that of this cohort, 97.3% 
of patients were able to remain conserved (173). However, of the patients 
with an absent mammographie nidus this was only possible in 38% of 
cases due to the presence of positive margins (173). Similarly, Kollias et 
al found that histologically involved margins were associated with both 
the presence of microcalcifications and the absence of a mammographie 
nidus (174). Kini et al reviewed the data on 400 patients undergoing 
breast-conserving surgery and found a local recurrence rate within this 
population of 9.2% (175). When Kini et al reviewed the results from 214 
mammograms available for analysis, the incidence of positive margins 
among patients with mammographie microcalcification was 22% 
compared to 6% for those without (175).
A previous study fi*om this institution examined the correlation between 
pre-operative mammographie features and risk factors for the 
development of local recurrence (29). Macmillan et al reviewed the pre­
operative mammographie features from 231 patients undergoing breast- 
conserving surgery (29). All mammograms were independently reviewed 
by a single pathologist blinded to the clinico-pathological features of 
these patients (29). In this series the incidence of EIC was 22.1% (29).
The presence of casting calcification, absent mammographie nidus as 
well as a stellate nidus all predicted for EIC (29). Furthermore, the
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incidence of positive tumour margins within this study was 40% (29). 
This correlates well with the previously published literature from this 
institution (61). The presence of a DY mammographie pattern (178); 
casting microcalcification and the absence of a mammographie nidus 
were all found to be risk factors for the presence of residual disease 
within the tumour bed (29). When all three of these mammographie 
features were present however, the incidence of tumour bed positivity 
rose from 40% to 89% (29).
In summary, certain mammographie features have been shown to detect 
clinico-pathological risk factors for the development of local recurrence. 
Thus mammography can provide the clinician with a valuable tool that 
aids in the selection of those patients suitable for breast-conserving 
surgery. The aim of this study is to expand upon previous work linking 
pre-operative mammographie findings with established clinico- 
pathological risk factors for the development of local recurrence.
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PATIENTS AND METHODS
Patients
Of the 543 patients who had tumour bed assessment performed (chapter 
one) pre-operative mammographie data was available on 357 patients 
(Table 3.1). The mean age of patient was 56 years (range 27-83, S.D 
9.37). All patients had breast-conserving surgery performed and of these, 
307 (86%) patients had a level II axillary clearance performed.
Table 3.1: Clinico-pathological features
Clinico-pathological features
Sym ptom atic presentation 237 (6 6 )
Screen-detected  palpable tum ours 22 (6 )
Screen-detected  im palpable tum ours 98 (2 8 )
Invasive ductal carcinom a 301 (8 4 )
L obular carcinom a 22 (6 )
Special type 34 (1 0 )
A xillary nodal d isease 77/307 (25)
O estrogen receptor positivity 250 (7 0 )
T otal num ber o f  cases 357
Values in parentheses are percentages
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Surgery and pathological assessment
Surgical technique and pathological assessment has been described in 
chapter one.
Mammographie interpretation
All patients in this study had bilateral cranio-caudal (cc) and oblique 
mammograms performed pre-operatively. All mammograms were 
reviewed by a single radiologist blinded to the pathological results. Table 
3.2 represents the mammographie features assessed in all patients. 
Illustrations 3.1-3.4 represent some of the pre-operative mammographie 
features identified in this group of patients.
Statistical analysis
The relationship between clinico-pathological factors and tumour bed 
positivity with mammographie features was analysed using the Pearson’s 
chi squared and the Independent sample t-tests. In order to perform a 
multivariate analysis of the mammographie factors that predict for tumour 
bed positivity a stepwise logistic regression analysis was performed.
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Table 3.2: Mammographie features assessed in all patients
Mammographie features
Side o f  lesion Right Vs Left
N um ber o f  lesions
B reast quadrant UOQ, UIQ, LOQ, LIQ and Retroaerolar
C lock
B reast density* Fatty (Nl) ; Mixed (P1&P2): Dense (DY)
L esion type Spiculated mass : dense nidus 
Spiculated mass : fatty nidus 
Ill-defined non-spiculated mass 
Partly-defined non-spiculated mass 
Well-defined non-spiculated mass 
Distortion 
Asymmetry 
Micro calcification
M icro-calcification Present vs absent
M icro-calcification  type Casting vs non-casting
Size o f  n idus (excluding spicules) Oblique view mm 
CC view mm 
Maximum diameter mm
T otal size o f  lesion (includ ing spicules) Oblique view mm 
CC view mm 
Maximum diameter mm
N idus to nipple d istance Oblique view mm 
CC view mm 
Maximum diameter mm
B reast size Oblique view mm 
CC view mm
* For the purposes of this study PI and P2 type Wolfe patterns were grouped together 
to form the “mixed” mammographie pattern.
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Illustration 3.1: Dense mammographie pattern with absent
nidus and presence of casting calcification
172
Illustration 3.2: Fatty mammographie pattern with non-
stellate lesion
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Illustration 3.3: Casting microcalcification
174
Illustration 3.4: Stellate lesion
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RESULTS
Correlation between mammographie features and clinico-pathological 
factors
The mean age of patient with a dense mammogram was 52 years 
compared with 56 years for a fatty mammographie pattern,/?=0.027. No 
association was found between type of mammographie abnormality -  for 
example the combination of an absent mammographie nidus with the 
presence of casting calcification and mode of presentation.
The presence of extensive in-situ disease within the tumour was 
associated with both casting calcification and absence of a 
mammographie nidus (p=0.0001 and 0.002 respectively) but not with 
mammographie density. Furthermore, no association was found between 
absent mammographie nidus, casting calcification or breast density with 
tumour grade or type.
176
Correlation between mammographie features and tumour bed positivity
All patients in this study had tumour bed assessment performed and the 
incidence of tumour bed positivity was 37%. The correlation between 
tumour bed positivity and pre-operative mammographie features is 
presented in Table 3.3. Of note was the association between casting 
calcification (p=0.003), absence of a mammographie nidus (p=0.027), 
maximum nidus size (p=0.014) as well as the ratio of maximum 
mammographie abnormality to breast size (p=0.017 cranio caudal view 
and p=0.045 oblique view) with tumour bed positivity. No association 
was found between breast density and tumour bed positivity.
The overall incidence of tumour bed positivity in this group of patients 
was 37. However, when both an absent mammographie nidus and casting 
calicification were present the incidence of tumour bed positivity rose 
to 60%.
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Table 3.3: Correlation between mammographie features and
tumour bed positivity
Mammographie feature T u m our bed positive T um our bed negative
B reast density
Fatty (Nl) 18(31) 39 (69)
Mixed (PI & P2) 78 (37) 133 (63)
Dense (DY) 36 (40) 53 (60)
C alcification
Casting 35 (56)* 28 (44) *p=0.003
Non-casting 23 (34) 45 (66)
Absent 74 (33) 152 (67)
N idus
Stellate 62 (40) 93 (60)
Non-stellate 51 (31) 115 (69)
Absent 19 (53)* 17 (47) *p=0.027
N ipple to n idus oblique (m m ) 80 76
N ipple to  n idus cc (m m ) 79 75
M axim um  m am m ographie  
abnorm ality  (m m )
35 32
M axim um  nidus size (m m ) 19* 16 p=0.014
B reast size oblique (m m ) 100 107
B reast size cc (m m ) 91 96
R atio  m axim um  
m am m ographie abnorm ality  
to breast size (oblique)
0.27* 0.22 p=0.045
R atio  m axim um  
m am m ographie abnorm ality  
to breast size (cc)
0.32* 0.25 p=0.017
T otal num ber o f  cases 132 225
* Indicates significant values
• Values in parentheses are percentages
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Multivariate analysis ofpredictors o f tumour bed positivity
A multivariate analysis of all the factors which predicted for tumour bed 
positivity was performed, Table 3.4. On performing this analysis only the 
presence of casting calcification predicted for tumour bed positivity, 
p=0.0275 (relative risk 2.7169, 95% confidence interval 1.1917-6.1941).
Table 3.4: Multivariate analysis of predictors of tumour bed 
positivity
F actor S ign ificance (p- 
value)
R elative R isk 95%  C onfidence  
Interval
M axim um  nidus size  
(m m )
0.0582 0.9629 0.9259-1.0013
A bsent
nidus
0.4060 1.0309 0.3750-2.8337
C asting
calcification
0.0175 2.7169 1.1917-6.1941
R atio  n idus/breast size  
(ob lique v iew )
0.7854 0.01 0.0033-2 .9987
R atio  n idus/breast size  
(cc view )
0.2426 0.5 0.1563-1.5991
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DISCUSSION
Local recurrence is a matter of concern to both the surgeon and patient. It 
not only undermines patient morale it often leads to a mastectomy, thus 
negating one of the main goals of breast-conserving surgery. Over recent 
years however, local recurrence is being seen in a more sinister light as 
the harbinger of systemic disease, even if a causal relationship between 
these two factors has yet to be determined. Of the risk factors for local 
recurrence inadequate tumour excision remains paramount. Tumour bed 
assessment has been previously shown to be able to detect a high 
incidence of residual disease within the tumour bed (61).
Due to the importance of avoiding local recurrence It is vital to scrutinise 
patients prior to offering breast-conserving surgery. The usual parameters 
that determine the choice of surgery apart from patient preference are 
tumour size and position within the breast. However, there have been 
studies showing certain pre-operative mammographie features that predict 
for clinico-pathological risk factors for the development of local 
recurrence. The presence of microcalcification, as well as absence of 
mammographie nidus, have been found to be predictors for the presence 
of ETC (169-170). These mammographie features have also been found to 
be risk factors for positive tumour margins (171-175). This institution
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previously reported results showing that presence of casting calcification, 
absent mammographie nidus and a dense mammographie pattern were all 
risk factors for the presence of positive tumour margins (29). Similarly 
EIC was associated with both casting calcification and absence of a 
mammographie nidus (29).
This study confirms the earlier findings with regards to predictors of a 
positive tumour margin and EIC. An association was also found between 
the size of the mammographie abnormality and positive tumour margin. 
On performing a multivariate analysis however only the presence of 
casting calcification predicted for positive tumour margins. Unlike the 
previous study the presence of a dense mammographie pattern was not 
found to be associated with tumour bed positivity. This finding may be 
due to inter-observer variation as a different radiologist interpreted 
mammographie findings in the current when compared to the previous 
study. Furthermore, the larger numbers of patients analysed in the current 
study may also have influenced this result.
The findings from this work have important implications for the pre­
operative identification of those patients unsuitable for breast-conserving 
surgery. Recent developments in radiological imaging techniques such as 
magnetic resonance imaging have already shown their ability to detect
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extensive disease throughout the breast that makes such patients 
unsuitable for limited resections (179-188). Buuchberger et al 
prospectively performed magnetic resonance imaging on 254 patients and 
found that 30% of patients had extensive disease throughout the breast 
making such patients unsuitable for breast-conserving surgery (179). 
Furthermore, Palinedo et al compared mammography with magnetic 
resonance imaging and found that the sensitivity of detecting occult 
disease with magnetic resonance imaging was greater than that with 
conventional mammography 91% versus 60% (180). However, this result 
was only observed among patients with palpable lesions (180). One fact 
that may explain this difference is that this study contained only 56 
patients (180). A larger trial may be needed for the sensitivity of magnetic 
resonance imaging in impalpable lesions to reach significance. 
Furthermore, Date et al found that magnetic resonance imaging was able 
to detect intra-ductal extensions up to 1cm fi'om the primary tumour in 
52% of cases (188).
In summary this study has demonstrated several pre-operative 
mammographie features that predict for both EIC and positive tumour 
margins. These findings can be used to assist the clinician in identifying 
those patients who may be unsuitable for breast-conserving surgery. 
Furthermore a positive tumour margin is regarded as a risk factor for the
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development of local recurrence, the onset of which has been shown to be 
a predictor of poorer survival. Thus the presence of pre-operative 
mammographie features predictive of tumour bed positivity may also be a 
surrogate marker for a biologically more aggressive tumour. This finding 
has obvious implications for subsequent adjuvant therapy offered to such 
patients. Despite this, the importance of accurate assessment of the 
tumour margin as well as rigorous follow up cannot be underestimated.
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CHAPTER 4 
INTRODUCTION
The effect of local recurrence on patient survival is a matter of intense 
debate. Recent studies have shown that there may be a link between the 
development of local and systemic recurrence (32,38). However it is 
difficult to determine any such correlation. Risk factors such as tumour 
size; lymphovascular invasion and tumour grade and type that predict for 
local recurrence, are also risk factors for the development of systemic 
recurrence. This aligned to the fact that when considering the effect of 
local on systemic recurrence the impact of lead-time bias has to be taken 
into account makes any study setting out to determine such a correlation 
extremely difficult to design.
Data collected from the NSABP-B06 trial has shown marked differences 
in the rates of local recurrence rates between those offered post-operative 
radiotherapy and those who were not (38). However, despite these 
differences in local recurrence rates, there was no significant difference in 
overall survival among the various treatment arms of this trial (38). 
However, when patients who suffer a local recurrence were analysed as a 
separate population and outcomes assessed, it was noted that the relative
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risk of developing systemic disease increased to between 1.2 to 6.6 
(32,38). In the NSABP-B06 trial when a time dependent multivariate 
analysis was performed the presence of local recurrence was found to be 
a predictor of systemic recurrence (38). Veronesi et al found similar 
results when they reviewed their experience of 2233 patients (32). In the 
NSABP-B06 trial it was shown that patients with local recurrence 
occurring within 1 year of the initial surgery had a higher incidence of 
systemic recurrence (38). Similarly, Veronesi showed the relative risk of 
developing systemic disease to be 6.6 if the local recurrence had occurred 
within one year of surgery (32). This risk fell to 2.2 and then to 1.2 for 
local recurrences occurring firstly 2 and then 3 years following surgery 
(32). Furthermore, analysis of results of the OCOG trial has shown that 
local recurrence is associated with poorer survival (62). Similarly,
Chauvet et al showed that the 5-year survival was 87.5% for those with 
local recurrence compared to 91.3% for those without (115). These 
results have been repeated in other studies (31,116-126).
Recognised risk factors for local recurrence include poorer tumour grade; 
extensive in-situ disease within the tumour and lymphovascular invasion. 
However the major risk factor for developing local recurrence is 
inadequate tumour excision. The technique of tumour bed assessment has 
been shown to detect a high incidence of residual disease following wide-
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local excision (61). Macmillan et al showed that tumour bed positivity 
was a predictor of poorer distant disease-free survival (189). This group 
also found that patients who underwent further surgical excision for a 
positive tumour margin had the poorest distant disease-free survival 
(189). This fact suggests that patients with a positive margin may form a 
subgroup with aggressive tumours and that the poor distant disease-free 
survival seen in this group may be independent of residual disease within 
the breast. This effect on poorer survival appears to be independent of 
axillary nodal status (189),
Over the past decade there has been an increased interest in the detection 
of occult axillary nodal disease as detected by immunohistochemistry 
(IHC) and polymerase chain reaction techniques (PCR). Cote et al 
analysed the lymph nodes from 736 patients with node-negative breast 
cancer (190). The nodes were serially sectioned and stained by both 
Haematoxylin and Eosin as well as by IHC (190). This team found that 
IHC detected occult disease in 20% of cases compared to 7% with 
Haematoxylin and Eosin staining (190). Other teams have found similar 
results (191-192). Although IHC has been found to detect an increased 
incident of occult disease, the results from the literature seem to be 
varied. In a review by Dowlatshahi et al IHC appeared to increase the 
detection rate of occult disease by between 9-33% (193). This variation
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may in part be explained by the differing numbers of patients included in 
these diverse studies as well as differences in the types of antibodies 
used. Similar variations in the detection rate of occult disease by PCR 
have been noted 9 to 66% (194-197). Unfortunately due to the use of 
differing markers for PCR as well as the relatively small numbers 
included within the above studies a consensus regarding the effectiveness 
of PCR is difficult to establish. However, when Noguchi et al performed 
a study directly comparing the two techniques, PCR was able to detect 
occult disease that was missed on IHC (198).
The impact of occult axillary disease on patient outcome has been a 
matter of some debate. This subject has been made more difficult by the 
fact that in the literature occult tumour deposits have been categorised as 
being either micro- or macro-metastases with varying cut of points of 
between 0.2 to 2mm (193). Furthermore, some of these studies contain 
relatively small cohorts of patients making a statistical analysis of 
survival difficult to interpret (192, 196,199). Despite these reservations 
several studies have found an association between occult axillary disease 
and poorer survival (190,192,196,199-201). Cote et al found that the 
presence of occult disease detected by IHC was a predictor of poorer 
distant-disease free survival, relative risk of 1.79 (190). This relationship 
however was only significant among post-menopausal women (190). A
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study by the “international breast cancer study group” reviewed the nodal 
pathology of 921 patients and found that occult disease was present in 9% 
of cases (201). This group found that occult disease was a predictor of 
poorer overall survival (201). Elson et al however found no such 
relationship (191). This study was however based on a relatively small 
cohort of 97 patients thus making any statistical analysis of outcome 
difficult to interpret (191).
The type of occult disease found within the axilla may also have a bearing 
on patient outcome. Hartveit et al reviewed the nodal pathology from 
1069 patients and found that 15% had occult disease as detected by serial 
sectioning of the node (200). When these patients were further analysed 
occult disease within the nodes was found to be one of two variants, 
either deposits within the sub-capsular tissue or within the lymphoid 
tissue itself (200). Hartveit et al found that patients with micro-metastases 
within the lymphoid tissue had a better outcome compared to those with 
disease confined to the capsule (200). This study is however hampered by 
that fact that neither IHC nor PCR was used in the analysis of nodal 
tissue. Thus Hartveit’s team may well have underestimated the incidence 
of occult disease thus biasing their results. Lockett et al found that the 
extent of marker positivity on PCR predicted for poorer survival (196).
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However this study dealt with a small cohort of only 37 patients in whom 
any statistical comment on outcome would be inaccurate (196).
In summary local recurrence has been shown to be a predictor of poorer 
survival. Inadequate tumour excision as detected by tumour bed 
assessment is one of the major risk factors for the development of local 
recurrence. Furthermore, Macmillan et al showed that tumour bed 
positivity was a predictor of poorer survival and that this relationship was 
independent of the axillary nodal status (189). The aim of this study is to 
assess whether there is a correlation between tumour bed positivity and 
occult disease within the axilla, a feature that would help explain the 
poorer outcome observed in patients with a positive margin.
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PATIENTS AND METHODS
Patients
The data presented in this study relates to the cohort of patients dealt with 
in chapter one. A decision was made to initiate a pilot study designed to 
assess the relationship between tumour bed positivity and occult nodal 
disease. A subgroup of the 543 patients from chapter one was chosen for 
this study. This involved a “study” as well as a “control” group. The 
numbers included in the “study” group were all those patients who had 
cavity shavings performed, were node negative and who went onto 
develop systemic recurrence. This cohort consisted of 19 patients. Of 
these, 10 patients had positive cavity shavings.
The control group consisted of 19 patients again all of whom had no 
axillary nodal disease and were alive and well at the end of follow-up. 
These patients were matched with the study group according to cavity 
shaving status; tumour type and grade; pathological tumour diameter; 
oestrogen receptor status and age at diagnosis.
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Follow-up
The follow-up of patients in this study range from 15 to 100 months 
(mean 43 months). The mean follow-up of the study group was 33 
months compared to 48 months for the control group.
Statistical analysis
The Pearson’s chi-squared and Independent sample t-tests were used to 
assess any significant differences between the study and control group’s 
clinico-pathological factors. These tests were also used to correlate 
clinico-pathological features and tumour bed positivity with the presence 
of occult axillary nodal disease. A 5% significance level was used 
throughout this analysis.
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Immunohistochemistry
In order to enhance detection of occult disease a decision was made in 
conjunction with a specialised breast pathologist to re-section lymph node 
specimens at a 3-micron interval compared to the conventional 5-micron 
interval currently being used within this institution. Furthermore, multiple 
sections of each block of tissue were prepared for conventional 
histological examination. Due to the availability of resources within the 
pathology department after discussion with the specialist pathologist 
involved with this study a decision was made to use IHC rather than PCR 
to detect occult disease.
A total of 276 blocks of tissue containing 392 nodes were examined. A 
total of four slides were prepared from each block of tissue with two 
being used for immunohistochemical staining and one being used for 
Haematoxylin and Eosin preparation. Two antibodies that are routinely 
used within this institution in the analysis of breast cancer were used to 
stain the tissue, MNF 116 a cytokeratin marker (provided by Daco: 1:125 
dilution) and MUC 1 CORE that stains for mucin (provided by 
Novocastra: 1:125 dilution). The fourth slide from each block was left 
unstained but underwent the process of fixation as a negative control to 
ensure that the technique of preparation of the slides did not influence the
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outcome. Positive controls of breast cancer tissue were also included in 
order to assess the efficacy of the antibodies used. An independent 
pathologist who was blinded to overall patient histology and outcome 
assessed the prepared slides.
Following sectioning the slides were ovened for at least 30 minutes at 60 
degrees centigrade. The slides were then “dewaxed” by being placed in 
Xylene for 10 minutes and then rinsed in alcohol (3 changes) and finally 
rinsed in tap water for a few seconds. Endogenous peroxidase activity 
was then quenched by placing the slides in a 3% aqueous solution of 
hydrogen peroxide for 10 minutes.
In the case of the MUC 1 antibody antigen retrieval was achieved by 
microwaving the tissue for a period of 10 minutes. During this process 
the slides were placed in plastic containers filled with lOmM citrate 
buffer (pH 6). In the case of the MNF cytokeratin antibody however, 
antigen retrieval was achieved by placing the slides in a water bath at 37 
degrees centigrade in a solution of 0.1% trypsin and 0.1% calcium 
chloride. The slides were then left to incubate for 10 minutes following 
which they were rinsed in cold water. The next step involved application 
of the “blocker”, namely normal horse serum (1:60 dilution). After 
incubation with the “blocker” for 10 minutes the primary antibody was
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applied. The slides were then left to incubate for 30-45 minutes at room 
temperature. Following this step the secondary antibody, namely 
biotinylated rabbit anti-mouse (1 ;400 dilution in normal horse serum) was 
added and the slide left to incubate at room temperature for a further 30 
minutes. The sections were then washed for 30 minutes before the third 
layer was applied. Streptococcal ABC antibody (1:100 dilution) was then 
added and the slides were incubated for a further 30 minutes at room 
temperature. The slide was then washed for a further 30 minutes. 
Visualisation of the antibody was performed by the addition of 
diaminobenzadine (DAB) to the slide which was then left to incubate for 
a further 10 minutes in a “safety cabinet” before being finally rinsed in 
water prior to mounting.
Illustration 4.1 represents a diagrammatic representation of the 
antibody/antigen binding process. Illustration 4.2-4.3 represents MNF 
116-cytokeratin and MUC-1 CORE positive controls. Illustrations 4.4-4.6 
represent tissue containing occult disease stained by H&E, MNF and 
MUC-1 representatively.
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Illustration 4.1: Diagrammatic representation of the
antibody to antigen binding process
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Illustration 4.2: Positive control (MNF 116-cytokeratin)
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Illustration 4.3: Positive control (MUC-1 CORE)
%
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Illustration 4.4: Haematoxylin & Eosin stained node with
micro-metastasis
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Illustration 4.5: MNF 116-cytokeratin stained micro
metastasis
€
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Illustration 4.6: MUC-1 CORE stained micro-metastasis
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RESULTS
The mean age of patient was 55 years (range 42-69 years, S.D. 7.18 
years). The mean number of axillary nodes retrieved was 10 (range 2-30 
nodes). Of the tumour bed positive patients in the study group 5 (50%) 
patients had invasive disease within the cavity shavings and the 
remaining patients had residual in-situ disease only.
Results of patient pathology and underlying differences between the 
study and control groups are represented in Table 4.1.There was no 
significant difference between the study and control groups for age at 
diagnosis; pathological tumour diameter; oestrogen receptor status; 
tumour grade or type.
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Table 4.1: Clinico-pathological factors
Study group C ontrol group
M ean age (years) 56 51 p= 0 .108
Invasive ductal 
carcinom a
1 8 (9 5 ) 19 (100)
L obular
carcinom a
1 (5) 0
G rade I 0 1 (5)
G rade II 9 (47) 8 (42)
G rade III 9 (47) 10 (53)
N ot defined 1 (6)
M ean  tum ou r d iam eter  
(m m )
15.6 14.6 /7=0.102
O estrogen  receptor  
positive
8 (42) 10 (53) p=0.089
T u m our bed  
positive
10 (53) 9 (47)
T otal num bers o f  
patien ts in each colum n
19 19
Values in parentheses are percentages
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Clinico-pathological factors and occult axillary disease
This study identified that only 2 (5.6%) of the patients had occult axillary 
disease, Table 4.2. Due to these small numbers with occult axillary 
disease, no statistical associations could be made between clinico- 
pathological factors and tumour bed positivity with occult axillary 
disease. It is worthy of note however, both patients with occult axillary 
disease were tumour bed positive.
Table 4.2: Clinico-pathological features of patients with 
occult axillary disease
Clinico-pathologicalfeatures Patient 1 Patient 2
A ge (years) 58 43
T u m our type Invasive ductal 
carcinoma
Invasive ductal 
carcinoma
T um our grade II III
T u m our size (m m ) 6 30
O estrogen  receptor status Positive Negative
C avity  shaving status Positive (invasive 
disease)
Positive (in-situ 
disease only)
O utcom e Well Systemic
recurrence
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DISCUSSION
The development of metastatic disease is a complex process involving a 
series of selective events, all of which depend on the complex interaction 
between host and tumour factors (202). One factor being recently 
highlighted as an independent predictor of poorer survival is the presence 
of residual disease within the tumour bed (186). Furthermore, the effect 
of tumour bed positivity on poorer outcome seemed to be independent of 
the presence of residual disease or nodal status (186). These findings 
suggest that patients with a positive margin have aggressive tumours.
This finding has important implications for clinical practice as tumour 
bed positivity is found in 37% of patients undergoing breast-conserving 
surgery (61).
The traditional methods of staging patients with breast cancer are 
relatively insensitive at detecting the presence of occult disease. The use 
of IHC or PCR techniques to detect tumour specific markers are more 
sensitive methods detecting the presence of micro-metastases within the 
axilla and have been found to detect occult disease in up to 33% of cases 
(190-192,194-197,203). Sentinel node biopsy is a new technique that uses 
the combination of staining with blue dye and radioisotope labelling to 
detect the first draining node from a tumour. This technique combined
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with IHC or PCR may one-day lead to a highly efficient method of 
detecting occult disease within the axilla (204-215).
The aim of this study was to detect any association between tumour bed 
positivity and occult axillary disease. Such a finding would correlate well 
with Macmillan’s results (189). In this study a total of 38 patients with 
392 separate node were analysed for the presence of occult disease by the 
combination of serial sectioning and IHC. The expected detection of 
occult disease as assessed by IHC would be approximately 20 % (190- 
192). In this limited series however only 2 (5.6%) patients were found to 
have occult disease. There was no association found between tumour bed 
positivity and occult disease within the axilla. Furthermore, only 1 of the 
19 patients who developed systemic recurrence had occult disease within 
the axilla. The major limitation of this study however is the small 
numbers of patients that were available for analysis. However, these 
results do show that within this institution the traditional method of nodal 
staging missed disease in only 2/392 nodes. This result is better than the 
published data where serial sectioning detected missed foci of disease in 
up to 15% of cases (200). This finding may be explained in part by the 
fact that within this institution a specialist pathologist reports on all breast 
cancers.
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The results from this study highlight the need for a larger trial to be 
conducted in order to determine the exact incidence of occult nodal 
disease in patients with positive margins as a whole. An advantage of 
such a study would be that with follow-up data the effect of occult 
axillary disease on patient outcome could be analysed separately.
In summary, this study has not demonstrated any association between 
tumour bed positivity and the presence of occult disease within the axilla. 
These results are however due to the small numbers of patients included 
in this study. The results from this study further highlight the complexity 
of the metastatic process seen in breast cancer.
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CONCLUSION
With the better understanding of cancer biology as well as the 
development of safer forms of radiotherapy the management of operable 
breast cancer has progressed from radical forms of mastectomy to simple 
mastectomy and finally to breast-conserving surgery. Several trials have 
shown that breast-conserving surgery is a safe alternative to mastectomy
(15,16,38). The aim of breast-conserving surgery in the treatment of 
breast cancer is to excise the tumour completely and achieve an excellent 
cosmetic result. This must not however compromise the degree of local 
control allowed by mastectomy. The decision to opt for breast-conserving 
surgery is based on several factors including tumour size; site and patient 
preference. The consequences of inappropriately selecting patients for 
breast-conserving surgery are, re-operation (re-excision or mastectomy) 
in order to obtain disease-free excision margins or at worst, local 
recurrence.
Local recurrence following breast-conserving surgery is a matter of 
continuing clinical concern. The reported incidence of local recurrence is 
0.3 to 15% (17,38,62-64). Furthermore, local recurrence has been 
reported in up to 43% of patients not receiving post-operative 
radiotherapy (38). The presence of local recurrence not only
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undermines patient morale but may also predict for poorer survival. When 
patients who suffer a local recurrence are analysed as a separate 
population and their outcomes assessed, it has been noted that the relative 
risk of developing systemic disease increases to between 1.2 to 6.6
(32,38).
In the NS ABP-B06 trial when a time dependent multivariate analysis was 
performed the presence of local recurrence was found to be a predictor of 
systemic recurrence (38). Veronesi et al found similar results when they 
reviewed their experience of 2233 patients (32). In the NSABP-B06 trial 
it was shown that patients who had a local recurrence occurring within 1 
year of the initial surgery had a higher incidence of systemic recurrence 
(38). Similarly, Veronesi showed the relative risk of developing systemic 
disease to be 6.6 if the local recurrence had occurred within one year of 
surgery (32). This risk fell to 2.2 and then to 1.2 for local recurrences 
occurring firstly 2 and then 3 years following surgery (32). Furthermore, 
analysis of results of the OCOG trial has shown that local recurrence is 
associated with poorer survival (62). Similarly, Chauvet et al showed that 
the 5-year survival was 87.5% for those with local recurrence compared 
to 91.3% for those without (115). These results have been repeated in 
other studies (31,116-126).
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Many risk factors for the development of local recurrence are recognised 
including larger tumour size; the presence of EIC; lymphovascular 
invasion and oestrogen receptor negativity. However, one of the most 
important risk factors is inadequate tumour excision. A number of 
different factors make the completeness of surgical excision difficult to 
determine. Firstly lumpectomy specimens usually have a large and 
irregular surface area, containing a non-uniform tumour, thus making 
analysis difficult. Furthermore, the pathologist commonly has to deal 
with specimens containing eccentric tumour extension (159). All these 
problems make gross assessment of tumour margin unreliable.
Several techniques have been developed to aid in the pathological 
assessment of the tumour margin. However, the two main techniques are 
“inking” and “tumour bed assessment”. The technique of inking has been 
previously described and found to detect a positive margin in 
approximately 10% of cases (38). A previous study from this institution 
has found that tumour bed assessment detects a high incidence of residual 
disease (61). Furthermore, although these two techniques are not wholly 
comparable, inking has been found to be inaccurate at predicting the 
presence of residual disease as detected by tumour bed assessment (162).
This thesis deals with five main issues. These are the incidence of tumour
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bed positivity; the clinico-pathological and mammographie risk factors 
for tumour bed positivity; the effect of tumour bed positivity on patient 
outcome; the effect of a policy of tumour bed assessment on the local 
recurrence rate and whether tumour bed positivity is a predictor of occult 
axillary disease.
In a series of 543 patients the incidence of tumour bed positivity was 37% 
(chapter one). The extent of this disease varied from 1 to 2 foci of in-situ 
disease within 1 block of tissue to extensive invasive disease throughout 
most of the cavity shavings. This figure correlates well with the 
previously published data (61), In the initial study from this institution by 
Macmillan et al the only clinico-pathological factor that predicted for 
tumour bed positivity was poorer tumour grade (61). However the results 
from this thesis suggest that a symptomatic presentation; poorer tumour 
grade; EIC and lymphovascular invasion all predict for tumour bed 
positivity (chapter one). Furthermore, there was an association between 
invasive disease within the tumour bed and axillary nodal disease 
(chapter one). This discrepancy is explained by the fact that in the current 
study there has been a larger cohort of patients analysed. Thus clinico- 
pathologic features that did not reach significance previously have now 
been proven to be predictors of tumour bed positivity.
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During the time frame of this study a pragmatic policy of further surgery 
was followed with a proportion of patients undergoing re-excision or 
mastectomy. Of the 37% of patients with a positive margin 42% 
underwent further surgery. Of the 58% patients who were tumour bed 
positive but did not undergo further surgery all had between 1 to 3 foci of 
disease confined to one block of tissue. Interestingly in the earlier study 
by Macmillan et al only 35.6% of patients with a positive margin 
underwent further surgery compared to 42% in this updated series (61). 
This suggests that there has been a gradual change with time towards 
further surgery if a positive tumour margin is present.
In summary the study in chapter one has shown several clinico- 
pathological features that predict for a positive tumour margin. 
Furthermore, all the risk factors for tumour bed positivity have also been 
previously shown to be independent risk factors for the development of 
local recurrence (17,31,32,34-38,42). This raises the possibility that the 
presence of poorer tumour grade; lymphovascular invasion and EIC may 
be markers of a more locally advanced disease process within the breast. 
Consequently in such cases a traditional wide local excision could leave 
behind residual disease that can eventually progress on to a local 
recurrence.
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The local recurrence rate achieved by this institution was 2% (mean 
follow-up 52 months) (chapter one). This figure compares favourably 
with the published literature (17,38,62-64). Furthermore, tumour bed 
positivity was found to be a predictor of both poorer DFS as well as 
DDFS (chapter one). These findings are similar to the previously 
published results (189). There was however no association between 
tumour bed positivity and either overall survival or local recurrence. 
Although patient follow-up ranged from 14 to 105 months (mean 52 
months) longer follow-up may be required before any effect of tumour 
bed positivity on overall survival can become evident. The absence of a 
relationship between tumour bed positivity and local recurrence is 
explained by the fact that those patients with extensive disease within the 
tumour bed went on to further surgery in order to ensure adequate tumour 
clearance, thus reducing their risk. Furthermore, the relationship between 
tumour bed positivity and poorer outcome appears to be independent of 
residual disease within the tumour bed or axillary nodal status. This 
suggests that those patients who have extensive residual disease at the 
onset form a subgroup of patients who have aggressive cancers.
In order to assess the impact of implementing a policy of tumour margin 
assessment on the local recurrence rate, the study described in chapter
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two was performed. In this study the local recurrence rate fell from 16% 
pre-1988 to 2.5% post-1988. This fall in local recurrence may be due to 
an improvement in the adequacy of local tumour excision provided by 
tumour bed assessment. However, these results may be biased by 
differences in clinico-pathological factors as well as adjuvant therapy 
between these two groups of patients. There were significantly more 
patients in the pre-1988 group that had larger tumour that were node 
positive and tended to be oestrogen receptor negative. Oestrogen receptor 
negativity has been shown to be a risk fact for local recurrence (45,46). A 
similar result has been found in this study. Also, larger tumour diameter 
has been shown to be a risk for local recurrence in both the Milan and the 
NSABP-B06 trials (32,16). Furthermore, differences in the extent of local 
surgical excision practised prior to 1988 may also have influenced the 
relatively high local recurrence rate witnessed prior to 1988. This is 
indicated by the fact that 32% of the local recurrences pre-1988 occurred 
within 1 year of surgery confirming inadequate tumour excision as being 
a major factor.
Mammography is an essential tool in the pre-operative assessment of 
patients undergoing surgery for breast cancer. In addition to revealing 
diagnostic radiological abnormalities, pre-operative mammographie
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features may also determine those patients that should be suitable for 
breast-conserving surgery. Several studies have found a correlation 
between pre-operative mammographie features and clinico-pathological 
risk factors for the development of local recurrence (169-177). A previous 
publication from this institution identified that an absent mammograhic 
nidus; casting calcification and mammographie density were predictors of 
tumour bed positivity (29). The study described in chapter three found 
that there was an association between casting calcification; absence of a 
mammographie nidus; maximum nidus size as well as the ratio of 
maximum mammographie abnormality to breast size with tumour bed 
positivity. On performing a multivariate analysis however only the 
presence of casting calcification predicted for tumour bed positivity, 
relative risk of 2.7169. Unlike the previous study the presence of a dense 
mammographie pattern was not found to be associated with tumour bed 
positivity. This finding may be due to the presence of inter-observer 
variation as a different radiologist interpreted mammographie findings in 
the current when compared to the previous study. Furthermore, the larger 
numbers of patients analysed in the current study may also have 
influenced this result.
Previous studies as well as the work contained within this thesis suggest
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that tumour bed positivity is a predictor of poorer survival (31,32,38,62). 
Furthermore, the impact on poorer outcome appears to be independent of 
the extent of residual disease within the breast or nodal status (189). This 
suggests that patients with a positive tumour margin form a subgroup of 
patients with aggressive disease. The advent of IHC and PCR has 
increased the ability to detect occult disease. In order to assess whether 
tumour bed positivity is associated with the presence of occult disease 
within the axilla the study in chapter four was performed. This study 
found that there was no association between tumour bed positivity and 
occult axillary disease. However, the relatively small numbers of cases 
included in the analysis limits the power of this study. Despite these 
results the impact of tumour bed positivity on poorer survival cannot be 
underestimated.
The main strength of this thesis is that the cohort of patients analysed is 
larger than in any previously published data from this unit. Thus several 
clinico-pathological risk factors of tumour bed positivity that did not 
reach significance previously have now reached significance. Also, the 
multivariate techniques used for analysis of the predictors of tumour bed 
positivity are strong statistical tests that have been used for the first time 
on this data. Furthermore, the study contained in chapter two is one of the
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few studies that directly analyses the impact of tumour bed assessment on 
the local recurrence rate. The fixed follow-up period of 5-years used in 
chapter two negates the effect of differing follow-up periods on patient 
outcome. Despite differences between the pre- and post-1988 cohorts that 
may have influenced outcome, this study has shown the benefits of 
tumour margin assessment on reducing the local recurrence rate.
Although the work within this thesis has its merits it also has several 
limitations. Firstly, this data was collected in a retrospective manner from 
a non-randomised cohort and thus is open to bias. Furthermore, the time 
frame for this study is over a 12-year period during which there were 
changes in both surgical as well as oncological practice. Also, the 
pathological data in this study was not reviewed. Thus for some of the 
earlier patients included in this study a specialist pathologist may not 
have reported the pathological slides raising the possibility of inaccuracy. 
These factors make analysis of such data difficult and again open to bias.
The main implication on clinical practice of this thesis is that meticulous 
care is needed during breast-conserving surgery to ensure adequate 
tumour excision in order to prevent local recurrence. This work has 
shown tumour margin assessment to be a simple technique that detects a
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high incidence of residual disease and its implementation can result in a 
low local recurrence rate. Furthermore, several clinico-pathological as 
well as mammographie risk factor for tumour bed positivity have been 
identified and these can be used to identify those patients that would not 
be suitable for breast-conserving surgery.
This thesis deals with many of the issues surrounding tumour margin 
assessment. However, there are several issues that require further 
analysis. The relationship between tumour bed positivity and poorer 
survival is of utmost importance as 37% of patients have disease within 
the tumour bed. There is the need for prospective randomised trials that 
assess the impact of tumour bed positivity on patient outcome as well as 
examining whether the use of adjuvant therapy in tumour bed positive 
patients alters their poorer prognosis. Furthermore, the study described in 
chapter four could be used as the basis for further work that determines 
both the incidence of occult axillary disease in patients with tumour bed 
positivity as well as the impact of such disease on patient outcome.
In summary the understanding of the mechanisms of local recurrence as 
well as its implications on patient outcome is of relevance to any clinician 
managing a patient with breast cancer. Anyone practising breast-
217
conserving surgery needs to ensure great care in achieving an adequate 
tumour clearance. There have been several techniques developed in order 
to achieve this goal of which the technique of tumour margin assessment 
has been shown to detect a high incidence of residual disease within the 
tumour bed. The implementation of a policy of tumour margin 
assessment combined with further surgery results in a low local 
recurrence rate. Furthermore, the relationship between tumour bed 
positivity and poorer survival has important implications, however this 
finding needs further investigation before changes can be made to current 
clinical practice. It is believed that the work contained within this thesis 
has helped improve our understanding of these specific aspects of patient
care.
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